CTI BioPharma (CTIC) 10-K 4 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 24, 2014	Jun. 28, 2013
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'CTIC	'	'
Entity Registrant Name	'CELL THERAPEUTICS INC	'	'
Entity Central Index Key	'0000891293	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	149,637,666	'
Entity Public Float	'	'	$106,673,063

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$71,639	$50,436
Accounts receivable	235	'
Inventory	5,074	1,626
Prepaid expenses and other current assets	3,567	8,249
Total current assets	80,515	60,311
Property and equipment, net	5,478	6,785
Other assets	7,730	6,617
Total assets	93,723	73,713
Current liabilities:	'	'
Accounts payable	5,051	12,065
Accrued expenses	9,469	10,209
Warrant liability	991	'
Current portion of deferred revenue	1,010	'
Current portion of long-term debt	3,155	'
Other current liabilities	393	393
Total current liabilities	20,069	22,667
Deferred revenue, less current portion	1,626	'
Long-term debt, less current portion	10,152	'
Other liabilities	5,657	4,641
Total liabilities	37,504	27,308
Commitments and contingencies	'	'
Common stock purchase warrants	13,461	13,461
Common stock, no par value:	'	'
Authorized shares-215,000,000 and 150,000,000 at December 31, 2013and 2012, respectively Issued and outstanding shares-145,508,767 and 109,823,748 at December 31, 2013 and 2012, respectively	1,933,305	1,872,885
Accumulated other comprehensive loss	-8,429	-8,273
Accumulated deficit	-1,879,703	-1,830,060
Total CTI shareholders' equity	45,173	34,552
Noncontrolling interest	-2,415	-1,608
Total shareholders' equity	42,758	32,944
Total liabilities and shareholders' equity	$93,723	$73,713

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, no par value	'	'
Common Stock, Authorized shares	215,000,000	150,000,000
Common Stock, Issued shares	145,508,767	109,823,748
Common Stock, outstanding shares	145,508,767	109,823,748

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Product sales, net	$2,314	'	'
License and contract revenue	32,364	'	'
Total revenues	34,678	'	'
Operating costs and expenses, net:	'	'	'
Cost of product sold	137	'	'
Research and development	33,624	33,201	34,900
Selling, general and administrative	42,288	38,244	38,290
Acquired in-process research and development	'	29,108	'
Settlement expense (income)	155	944	-11,000
Total operating costs and expenses, net	76,204	101,497	62,190
Loss from operations	-41,526	-101,497	-62,190
Other income (expense):	'	'	'
Investment and other income (expense), net	-546	-478	1,545
Interest expense	-1,026	-56	-870
Amortization of debt discount and issuance costs	-513	'	-546
Foreign exchange gain (loss)	61	344	-558
Total other expense, net	-2,024	-190	-429
Net loss before noncontrolling interest	-43,550	-101,687	-62,619
Noncontrolling interest	807	313	259
Net loss attributable to CTI	-42,743	-101,374	-62,360
Dividends and deemed dividends on preferred stock	-6,900	-13,901	-58,718
Net loss attributable to common shareholders	($49,643)	($115,275)	($121,078)
Basic and diluted net loss per common share	($0.43)	($1.98)	($3.53)
Shares used in calculation of basic and diluted net loss per common share	114,195	58,125	34,294

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net loss before noncontrolling interest	($43,550)	($101,687)	($62,619)
Other comprehensive income (loss):	'	'	'
Foreign currency translation adjustments	31	-168	241
Net unrealized loss on securities available-for-sale	-187	-70	-307
Other comprehensive loss	-156	-238	-66
Comprehensive loss	-43,706	-101,925	-62,685
Comprehensive loss attributable to noncontrolling interest	807	313	259
Comprehensive loss attributable to CTI	($42,899)	($101,612)	($62,426)

Consolidated_Statements_Of_Sha

Consolidated Statements Of Shareholder's Equity (Deficit) (USD $)

Total

Warrants

Series 8 preferred Stock

Series 9 preferred Stock

Series 10 preferred Stock

Series 11 preferred Stock

Series 12 preferred Stock

Series 13 preferred Stock

Series 14 Preferred Stock

Series 15 Preferred Stock

Series 16 Preferred Stock

Series 17 Preferred Stock

Series 18 Preferred Stock

Series 19 Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Accumulated Deficit

Accumulated Other Comprehensive Income (Loss)

Noncontrolling Interest

In Thousands, except Share data

Series 8 preferred Stock

Series 9 preferred Stock

Series 10 preferred Stock

Series 11 preferred Stock

Series 12 preferred Stock

Series 13 preferred Stock

Series 14 Preferred Stock

Series 15 Preferred Stock

Series 16 Preferred Stock

Series 17 Preferred Stock

Series 18 Preferred Stock

Series 19 Preferred Stock

Warrants

Series 9 preferred Stock

Series 11 preferred Stock

Series 12 preferred Stock

Series 13 preferred Stock

Series 14 Preferred Stock

Series 15 Preferred Stock

Series 16 Preferred Stock

Series 17 Preferred Stock

Series 18 Preferred Stock

Series 19 Preferred Stock

Beginning Balance at Dec. 31, 2010

($5,145)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

($1,576,643)

'

'

Stock Issued (in shares)

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative effect adjustment

-17,064

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-17,064

'

'

Conversion of preferred stock to common stock (in shares)

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending Balance at Jan. 31, 2011

-5,145

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,576,643

'

'

Beginning Balance at Dec. 31, 2010

-5,145

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,579,866

'

'

'

'

'

'

'

'

'

'

'

-1,576,643

-7,969

-399

Beginning Balance (in shares) at Dec. 31, 2010

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

27,125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

25,000

25,000

25,000

16,000

30,000

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued

'

21,198

18,337

25,000

18,301

24,957

10,647

19,077

13,472

'

'

'

'

'

'

18,337

25,000

18,301

24,957

10,647

19,077

13,472

'

'

'

'

'

'

21,198

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative effect adjustment

-17,064

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-17,064

'

'

Conversion of preferred stock to common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-25,000

'

-25,000

-16,000

-30,000

-10,000

'

'

'

'

'

'

'

2,149,000

2,469,000

1,521,000

3,529,000

1,739,000

'

'

'

'

'

'

'

'

Conversion of preferred stock to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-25,000

'

-24,957

-10,647

-19,077

-6,736

'

'

'

'

'

'

'

25,000

24,957

10,647

19,077

6,736

'

'

'

'

'

'

'

'

Redemption of preferred stock (Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-25,000

'

-25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of preferred stock

'

'

-18,337

'

-18,301

'

'

'

'

'

'

'

'

'

'

-18,337

'

-18,301

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of beneficial conversion features related to preferred stock

27,435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

27,435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of additional investment rights in connection with preferred stock issuances

7,742

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,742

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise or exchange of common stock purchase warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,616,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise or exchange of common stock purchase warrants

17,485

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,485

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

509,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation

5,017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noncontrolling interest

-259

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

-309

Other (Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-43,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other

-409

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-409

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends and deemed dividends on preferred stock

-58,718

'

-15,500

'

-15,400

'

-5,500

-13,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-58,718

'

'

Net loss for the year ended

-62,360

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-62,360

'

'

Other comprehensive loss

-66

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-66

'

Ending Balance at Dec. 31, 2011

28,009

'

'

'

'

'

'

'

'

'

'

'

'

'

6,736

'

'

'

'

'

'

'

'

'

'

'

'

1,744,801

'

'

'

'

'

'

'

'

'

'

'

-1,714,785

-8,035

-708

Ending Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

40,614,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance at Nov. 30, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued (in shares)

'

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock to common stock (in shares)

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending Balance at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,736

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock to common stock (in shares)

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending Balance at Jan. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance at Dec. 31, 2011

28,009

'

'

'

'

'

'

'

'

'

'

'

'

'

6,736

'

'

'

'

'

'

'

'

'

'

'

'

1,744,801

'

'

'

'

'

'

'

'

'

'

'

-1,714,785

-8,035

-708

Beginning Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

40,614,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000

15,000

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued

'

'

'

'

'

'

'

'

'

15,442

11,240

54,538

'

'

'

'

'

'

'

'

'

'

15,442

11,240

54,538

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock to common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

42,900,000

'

'

'

'

'

'

'

'

'

-10,000

-35,000

-15,000

-60,000

'

'

'

'

'

'

'

'

1,739,000

9,042,000

2,521,000

42,857,000

'

'

'

'

'

Conversion of preferred stock to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,736

-15,442

-11,240

-54,538

'

'

'

'

'

'

'

'

6,736

15,442

11,240

54,538

'

'

'

'

'

Value of beneficial conversion features related to preferred stock

13,901

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,901

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise or exchange of common stock purchase warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,687,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise or exchange of common stock purchase warrants

17,798

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,798

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,390,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation

7,938

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,938

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noncontrolling interest

-313

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

587

'

'

'

'

'

'

'

'

'

'

'

'

'

-900

Other (Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-26,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other

-96

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-96

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends and deemed dividends on preferred stock

-13,901

'

'

'

'

'

'

'

-8,900

'

'

-400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-13,901

'

'

Net loss for the year ended

-101,374

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-101,374

'

'

Other comprehensive loss

-238

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-238

'

Ending Balance at Dec. 31, 2012

32,944

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,872,885

'

'

'

'

'

'

'

'

'

'

'

-1,830,060

-8,273

-1,608

Ending Balance (in shares) at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

109,824,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued

'

'

'

'

'

'

'

'

'

'

'

'

14,859

29,840

'

'

'

'

'

'

'

'

'

'

'

14,859

29,840

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock to common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-15,000

-30,000

'

'

'

'

'

'

'

'

'

'

15,000,000

15,674,000

'

'

'

Conversion of preferred stock to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-14,859

-29,840

'

'

'

'

'

'

'

'

'

'

14,859

29,840

'

'

'

Value of beneficial conversion features related to preferred stock

6,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,207,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation

9,066

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,066

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noncontrolling interest

-807

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-807

Other (Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-196,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other

-245

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-245

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends and deemed dividends on preferred stock

-6,900

'

'

'

'

'

'

'

'

'

'

'

-6,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,900

'

'

Net loss for the year ended

-42,743

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-42,743

'

'

Other comprehensive loss

-156

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-156

'

Ending Balance at Dec. 31, 2013

$42,758

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,933,305

'

'

'

'

'

'

'

'

'

'

'

($1,879,703)

($8,429)

($2,415)

Ending Balance (in shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

145,509,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities	'	'	'
Net loss	($43,550)	($101,687)	($62,619)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Acquired in-process research and development	'	29,108	'
Equity-based compensation expense	9,066	7,938	5,017
Depreciation and amortization	1,570	2,346	2,411
Noncash interest expense	513	'	546
Provision for VAT assessments	'	-3,402	'
Other	365	5	-1,958
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-227	'	'
Inventory	-3,254	-1,586	'
Prepaid expenses and other current assets	4,530	-3,759	567
Other assets	-846	1,495	-2,452
Accounts payable	-5,774	3,123	-310
Accrued expenses	-834	-885	-211
Deferred revenue	2,636	'	'
Other liabilities	-25	4,528	-1,449
Total adjustments	7,720	38,911	2,161
Net cash used in operating activities	-35,830	-62,776	-60,458
Investing activities	'	'	'
Purchases of property and equipment	-1,657	-2,937	-2,703
Proceeds from sales of property and equipment	123	'	31
Cash paid for acquisition of assets from S*BIO Pte Ltd.	'	-17,764	'
Net cash used in investing activities	-1,534	-20,701	-2,672
Financing activities	'	'	'
Proceeds from issuance of long-term debt, net	14,501	'	'
Other	-244	-214	-424
Net cash provided by financing activities	58,972	87,216	87,004
Effect of exchange rate changes on cash and cash equivalents	-405	-355	529
Net increase in cash and cash equivalents	21,203	3,384	24,403
Cash and cash equivalents at beginning of year	50,436	47,052	22,649
Cash and cash equivalents at end of year	71,639	50,436	47,052
Supplemental disclosure of cash flow information	'	'	'
Cash paid during the period for interest	933	16	1,025
Cash paid for taxes	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Issuance of common stock upon exercise or exchange of common stock purchase warrants	'	17,798	17,485
Redemption of Series 8 and 10 preferred stock	'	'	36,638
Series 8 preferred stock, additional investment right and warrants	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity and warrants, net of issuance costs	'	'	23,213
Series 10 preferred stock, additional investment right and warrants	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity and warrants, net of issuance costs	'	'	23,530
Series 12 preferred Stock and Warrants	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity and warrants, net of issuance costs	'	'	14,962
Series 13 preferred stock and Warrants	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity and warrants, net of issuance costs	'	'	27,986
Series 14 Preferred Stock and Warrants	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity and warrants, net of issuance costs	'	-170	18,900
Series 15 Preferred Stock and Warrants	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity and warrants, net of issuance costs	'	32,856	'
Series 17 Preferred Stock	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity, net of issuance costs	-105	54,744	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	54,538	'
Series 18 Preferred Stock	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity, net of issuance costs	14,859	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	14,859	'	'
Series 19 Preferred Stock	'	'	'
Financing activities	'	'	'
Proceeds from issuance of equity, net of issuance costs	29,961	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	29,840	'	'
Series 16 Preferred Stock	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	11,240	'
Issuance of Series 16 preferred stock for acquisition of assets from S*BIO Pte. Ltd.	'	11,344	'
Series 9 preferred Stock	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	'	25,000
Issuance of preferred stock	'	'	25,000
Series 11 preferred Stock	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	'	24,957
Issuance of preferred stock	'	'	24,957
Series 12 preferred Stock	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	'	10,647
Series 13 preferred Stock	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	'	19,077
Series 14 Preferred Stock	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	6,736	6,736
Series 15 Preferred Stock	'	'	'
Supplemental disclosure of noncash financing and investing activities	'	'	'
Conversion of preferred stock to common stock	'	15,442	'
7.5% convertible senior notes	'	'	'
Financing activities	'	'	'
Repayment of convertible senior notes	'	'	-10,250
5.75% convertible senior notes	'	'	'
Financing activities	'	'	'
Repayment of convertible senior notes	'	'	($10,913)

Description_of_Business_and_Su

Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Description of Business and Summary of Significant Accounting Policies	'
	1	Description of Business and Summary of Significant Accounting Policies
	Description of Business
	We are a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is a high unmet medical need. We are primarily focused on commercializing PIXUVRI® (pixantrone) in the E.U. for adult patients with multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical program of pacritinib for the treatment of patients with myelofibrosis. As of the date of this filing, PIXUVRI was available in Austria, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Sweden and the United Kingdom.
	We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration, or FDA, in the United States, by the European Medicines Agency, or EMA, in the E.U. and by comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain and may take many years and may involve expenditure of substantial resources.
	Principles of Consolidation
	The consolidated financial statements include the accounts of CTI and its wholly-owned subsidiaries, which include Systems Medicine LLC, or SM, and CTI Life Sciences Limited, or CTILS. CTILS opened a branch in Italy in December 2009. We also retain ownership of our branch, Cell Therapeutics Inc. – Sede Secondaria, or CTI (Europe), however, we ceased operations related to this branch in September 2009. In addition, CTI Commercial LLC, a wholly-owned subsidiary, was included in the consolidated financial statements until dissolution in March 2012.
	As of December 31, 2013, we also had a 61% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements.
	All intercompany transactions and balances are eliminated in consolidation.
	Reverse Stock-Splits
	On May 15, 2011 and September 2, 2012, we effected one-for-six and one-for-five reverse stock splits, respectively, collectively referred to as the Stock Splits. Unless otherwise noted, all impacted amounts included in the consolidated financial statements and notes thereto have been retroactively adjusted for the Stock Splits. Unless otherwise noted, impacted amounts include shares of common stock authorized and outstanding, share issuances and cancellations, shares underlying preferred stock, convertible notes, warrants and stock options, shares reserved, conversion prices of convertible securities, exercise prices of warrants and options, and loss per share. Additionally, the Stock Splits impacted preferred stock authorized (but not outstanding because there were no shares of preferred stock outstanding as of the time of the applicable reverse stock split).
	Capital Requirements
	We expect that we will need to raise additional funds to develop our business. We may seek to raise such capital through debt financings, partnerships, collaborations, joint ventures or disposition of assets. Our Board of Directors may issue shares depending on our financial needs and market opportunities, if deemed to be in the best interest of the shareholders. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. Additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we may be required to delay, scale back, or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses and/or refrain from making our contractually required payments when due.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating reserves for sales deductions such as rebates and returns of product sold, allowances for credit losses, excess and obsolete inventory, share-based compensation expense, the allocation of our operating expenses, the allocation of purchase price to acquired assets and liabilities, restructuring charges and our liability for excess facilities, our provision for loss contingencies, the useful lives of fixed assets, the fair value of our financial instruments, our tax provision and related valuation allowance, and determining potential impairment of long-lived assets. Actual results could differ from those estimates.
	Certain Risks and Uncertainties
	Our results of operations are subject to foreign currency exchange rate fluctuations primarily due to our activity in Europe. We report the results of our operations in U.S. dollars, while the functional currency of our foreign subsidiaries is the euro. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, the reported carrying value of our euro-denominated assets and liabilities that remain in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. We review our foreign currency risk periodically along with hedging options to mitigate such risk.
	Financial instruments which potentially subject us to concentrations of credit risk consist of accounts receivable. The Company has accounts receivable from the sale of PIXUVRI from a small number of distributors and health care providers. Further, the Company does not require collateral on amounts due from its distributors and is therefore subject to credit risk. The Company has not experienced any significant credit losses to date as a result of credit risk concentration and does not consider an allowance for doubtful accounts to be necessary.
	Additionally, see Note 18, Customer and Geographic Concentrations, for further concentration disclosure.
	Concentrations
	We source our drug products for commercial operations and clinical trials from a concentrated group of third party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or if we were unable to obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.
	Cash and Cash Equivalents
	We consider all highly liquid debt instruments with maturities of three months or less at the time acquired to be cash equivalents. Cash equivalents represent short-term investments consisting of investment-grade corporate and government obligations, carried at cost, which approximates market value.
	Accounts Receivable
	Our accounts receivable balance includes trade receivables related to PIXUVRI sales as of December 31, 2013. We estimate an allowance for doubtful accounts based upon the age of outstanding receivables and our historical experience of collections, which includes adjustments for risk of loss for specific customer accounts. We periodically review the estimation process and make changes to our assumptions as necessary. When it is deemed probable that a customer account is uncollectible, the account balance is written off against the existing allowance. We also consider the customers’ country of origin to determine if an allowance is required based on the uncertainty associated with the recent European financial crisis. As of December 31, 2013, our accounts receivable did not include any balance from a customer in a country that has exhibited financial stress that would have had a material impact on our financial results. We did not record an allowance for doubtful accounts as of December 31, 2013.
	Value Added Tax Receivable
	Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable is approximately $5.7 million and $8.1 million as of December 31, 2013 and 2012, of which $5.6 million and $5.1 million is included in other assets and $0.1 million and $3.0 million is included in prepaid expenses and other current assets as of December 31, 2013 and 2012, respectively. The collection period of VAT receivable for our European operations ranges from approximately three months to five years. For our Italian VAT receivable, the collection period is approximately three to five years. As of December 31, 2013, the VAT receivable related to operations in Italy is approximately $5.6 million. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.
	Inventory
	We began capitalizing costs related to the production of PIXUVRI in February 2012 upon receiving a positive opinion for conditional approval by the EMA’s Committee for Medicinal Products for Human Use, or CHMP, at which time the likelihood of receiving conditional approval to market PIXUVRI in the E.U. was deemed probable. Production costs for our other product candidates continue to be charged to research and development expense as incurred prior to regulatory approval or until our estimate for regulatory approval becomes probable. We carry inventory at the lower of cost or market. The cost of finished goods and work in process is determined using the standard-cost method, which approximates actual cost based on a first-in, first-out method. Inventory includes the cost of materials, third-party contract manufacturing and overhead costs, quality control costs and shipping costs from the manufacturers to the final distribution warehouse associated with the production and distribution of PIXUVRI. We regularly review our inventories for impairment and reserves are established when necessary. Estimates of excess inventory consider our projected sales of the product and the remaining shelf lives of product. In the event we identify excess, obsolete or unsaleable inventory, the value is written down to the net realizable value.
	Property and Equipment
	Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets ranging from three to five years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful life of 10 years or the term of the applicable lease.
	Impairment of Long-lived Assets
	We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on fair market values.
	Leases
	We analyze leases at the inception of the agreement to classify as either an operating or capital lease. On certain of our lease agreements, the terms include rent holidays, rent escalation clauses and incentives for leasehold improvements. We recognize deferred rent relating to incentives for rent holidays and leasehold improvements and amortize the deferred rent over the term of the leases as a reduction of rent expense. For rent escalation clauses, we recognize rent expense on a straight-line basis equal to the amount of total minimum lease payments over the term of the lease.
	Acquisitions
	We account for acquired businesses using the acquisition method of accounting, which requires that most assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. Any excess of the consideration transferred over the fair value of the net assets acquired is recorded as goodwill, and the fair value of the acquired in-process research and development, or IPR&D, is recorded on the balance sheet. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date.
	Fair Value Measurement
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
	Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, or other inputs that are observable directly or indirectly.
	Level 3 – Unobservable inputs that are supported by little or no market activity, requiring an entity to develop its own assumptions.
	If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Financial Instruments
	At December 31, 2013 and 2012, the carrying value of financial instruments such as receivables and payables approximated their fair values based on the short-term maturities of these instruments. The carrying value of our long-term debt approximated its fair value at December 31, 2013 based on borrowing rates for similar loans and maturities.
	Contingencies
	We record liabilities associated with loss contingencies to the extent that we conclude the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note 14, Collaboration, Licensing and Milestone Agreements and Note 21, Legal Proceedings, for further information regarding our current gain and loss contingencies.
	Revenue Recognition
	We currently have conditional approval to market PIXUVRI in the E.U. Revenue is recognized when there is persuasive evidence of the existence of an agreement, delivery has occurred, prices are fixed or determinable, and collectability is assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria under the provision are met.
	Product Sales
	We sell PIXUVRI directly to health care providers and through a limited number of distributors. We generally record product sales upon receipt of the product by the health care providers and certain distributors at which time title and risk of loss pass. Product sales are recorded net of distributor discounts, estimated government-mandated rebates, trade discounts, and estimated product returns. Reserves are established for these deductions and actual amounts incurred are offset against the applicable reserves. We reflect these reserves as either a reduction in the related account receivable or as an accrued liability depending on the nature of the sales deduction. These estimates are periodically reviewed and adjusted as necessary.
	Government-mandated discounts and rebates
	Our products are subject to certain programs with government entities in the E.U. whereby pricing on products is discounted below distributor list price to participating health care providers. These discounts are provided to participating health care providers either at the time of sale or through a claim by the participating health care providers for a rebate. Due to estimates and assumptions inherent in determining the amount of government discounts and rebates, the actual amount of future claims may be different from our estimates, at which time we would adjust our reserves accordingly.
	Product returns and other deductions
	At the time of sale, we also record estimates for certain sales deductions such as product returns and distributor discounts and incentives. We offer certain distributors a limited right of return or replacement of product that is damaged in certain instances. When we cannot reasonably estimate the amount of future product returns and/or other sales deductions, we do not recognize revenue until the risk of product return and additional sales deductions have been substantially eliminated. To date, there have been no PIXUVRI product returns.
	Collaboration agreements
	We evaluate collaboration agreements to determine whether the multiple elements and associated deliverables can be considered separate units of accounting in accordance with ASC 605-25 Revenue Recognition – Multiple-Element Arrangements. If it is determined that the deliverables under the collaboration agreement are a single unit of accounting, all amounts received or due, including any upfront payments, are recognized as revenue over the performance obligation periods of each agreement. Following the completion of the performance obligation period, such amounts will be recognized as revenue when collectability is reasonably assured.
	The assessment of multiple element arrangements requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. In order to account for these agreements, we identify deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.
	Milestone payments under the collaboration agreement are generally aggregated into three categories for reporting purposes: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration, or FDA, or other countries’ regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.
	At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.
	Cost of Product Sold
	Cost of product sold includes third party manufacturing costs, shipping costs, contractual royalties, and other costs of PIXUVRI product sold. Cost of product sold also includes any necessary allowances for excess inventory that may expire and become unsalable. We did not record an allowance for excess inventory as of December 31, 2013.
	Research and Development Expenses
	Research and development costs are expensed as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC 730, Research and Development. Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. In instances where we enter into cost-sharing arrangements, all research and development costs reimbursed by the collaborator are a reduction to research and development expense while research and development costs paid to the collaborator are an addition to research and development expense. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.
Foreign Currency Translation and Transaction Gains and Losses
We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ equity (deficit), except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We and our subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions.
Income Taxes
We record a tax provision for the anticipated tax consequences of our reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax base of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. We record a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.
Net Loss per Share
Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and restricted stock using the treasury stock method.
Recently Adopted Accounting Standards
In December 2010, the FASB issued additional guidance on when to perform Step 2 of the goodwill impairment test for reporting units with zero or negative carrying amounts. The criteria for evaluating Step 1 of the goodwill impairment test and proceeding to Step 2 were amended for reporting units with zero or negative carrying amounts and require performing Step 2 if qualitative factors indicate that it is more likely than not that a goodwill impairment exists. For public entities, this guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2010. Upon adoption of this guidance on January 1, 2011, we performed Step 2 of the goodwill impairment test. Based on a valuation using the income, market and cost approaches, we determined that all of our $17.1 million in goodwill was impaired. The related charge was recorded as a cumulative-effect adjustment to beginning retained earnings on January 1, 2011. See Note 4, Goodwill, for additional information.
In June 2011, the FASB issued guidance amending the presentation requirements for comprehensive income. For public entities, this guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 with early adoption permitted. Subsequently, in December 2011, the FASB deferred the effective date of the portion of the June 2011 accounting standards update requiring separate presentation of reclassifications out of accumulated other comprehensive income as discussed below. Upon adoption on January 1, 2012, we had the option to report total comprehensive income, including components of net income and components of other comprehensive income, as a single continuous statement or in two separate, but consecutive statements. We elected to present comprehensive income in two separate, but consecutive statements as part of the accompanying consolidated financial statements.
In February 2013, the FASB issued guidance requiring presentation of amounts reclassified from each component of accumulated other comprehensive income. In addition, disclosure is required of the effects of significant reclassifications on income statement line items either on the face of the statement where net income is presented or as a separate disclosure in the notes to the financial statements. For public entities, this guidance was effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this guidance did not have a material impact on our consolidated financial statements.
Recently Issued Accounting Standards
In March 2013, the Financial Accounting Standards Board, or FASB, issued guidance to clarify when to release cumulative foreign currency translation adjustments when an entity ceases to have a controlling financial interest in a subsidiary or group of assets within a foreign entity. The amendment is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to derecognition events occurring after the effective date. Early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss or tax carryforward exists. FASB concluded that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset except in certain circumstances the unrecognized tax benefit should be presented as a liability and should not be combined with deferred tax assets. The amendment is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with early adoption permitted. We are currently evaluating the impact this amendment may have on our consolidated financial statements.
Reclassifications
Certain prior year items have been reclassified to conform to current year presentation.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory	'
	2	Inventory
	The components of inventories are composed of the following as of December 31, 2013 and 2012 (in thousands):
			2013		2012
	Finished goods		$	601	$	220
	Work-in-process			4,473		1,406
	Total inventories		$	5,074	$	1,626

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
	3	Property and Equipment
	Property and equipment is composed of the following as of December 31, 2013 and 2012 (in thousands):
			2013			2012
	Furniture and office equipment		$	10,913		$	11,743
	Leasehold improvements			5,078			5,077
	Lab equipment			143			411
				16,134			17,231
	Less: accumulated depreciation and amortization			(10,656	)		(10,446	)
			$	5,478		$	6,785
	Depreciation expense of $1.6 million, $2.3 million and $2.4 million was recognized during 2013, 2012 and 2011, respectively.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2013
Goodwill	'
	4	Goodwill
	In January 2011, we adopted the accounting standards update on Intangibles – Goodwill and Other (Topic 350), which provided additional guidance on when to perform Step 2 of the goodwill impairment test for reporting units with zero or negative carrying amounts. Upon adoption of the guidance, we determined that it was more likely than not that a goodwill impairment existed. On January 1, 2011, the implied fair value of goodwill for the reporting unit, after considering unrecognized in-process research and development, was zero. An impairment charge of $17.1 million was recorded in retained earnings as a cumulative-effective adjustment.
	The following table presents the effects of the cumulative-effect application (in thousands):
			Accumulated			Total Shareholders’
			Deficit			Deficit
	Balance at December 31, 2010		$	(1,576,643	)	$	(5,145	)
	Cumulative effect adjustment			(17,064	)		(17,064	)
	Adjusted Balance at January 1, 2011		$	(1,593,707	)	$	(22,209	)

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2013
Acquisitions	'
	5	Acquisitions
	In April 2012, we entered into an asset purchase agreement with S*BIO Pte Ltd., or S*BIO, to acquire all right, title and interest in, and assume certain liabilities relating to, certain intellectual property and other assets related to compounds SB1518 (also referred to as “pacritinib”) and SB1578, or the Seller Compounds. In consideration of the assets and rights acquired under the agreement, we made a payment of $15.0 million in cash and issued 15,000 shares of Series 16 convertible preferred stock, or Series 16 Preferred Stock, to S*BIO at closing in May 2012. Each share of Series 16 Preferred Stock had a stated value of $1,000 per share. In June 2012, all outstanding shares of our Series 16 Preferred Stock were automatically converted into 2.5 million shares of our common stock at a conversion price of $5.95 per share, subject to a 19.99% blocker provision.
	The total initial purchase consideration was as follows (in thousands):
	Cash		$	15,000
	Fair value of Series 16 Preferred Stock			11,344
	Transaction costs			2,764
	Total initial purchase consideration		$	29,108
	The transaction was treated as an asset acquisition as it was determined that the assets acquired did not meet the definition of a business. We determined that the acquired assets can only be economically used for the specific and intended purpose and have no alternative future use after taking into consideration further research and development, regulatory and marketing approval efforts required in order to reach technological feasibility. Accordingly, the entire initial purchase consideration of $29.1 million was immediately expensed to acquired in-process research and development for the year ended December 31, 2012. The contingent consideration arrangement as discussed below will be recognized when the contingency is resolved and the consideration is paid or becomes payable.
	As part of the consideration, S*BIO also has a contingent right to certain milestone payments from us up to an aggregate amount of $132.5 million if certain U.S., E.U. and Japanese regulatory approvals are obtained or if certain worldwide net sales thresholds are met in connection with any pharmaceutical product containing or comprising any Seller Compound for use for specific diseases, infections or other conditions. In addition, S*BIO will also be entitled to receive royalty payments from us at incremental rates in the low-single digits based on certain worldwide net sales thresholds on a product-by-product and country-by-country basis.
	At our election, we may pay up to 50% of any milestone payments to S*BIO through the issuance of shares of our common stock or shares of our preferred stock convertible into our common stock in lieu of cash.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accrued Expenses	'
	6	Accrued Expenses
	Accrued expenses consisted of the following as of December 31, 2013 and 2012 (in thousands):
			2013		2012
	Clinical and investigator-sponsored trial expenses		$	3,360	$	3,301
	Employee compensation and related expenses			3,035		3,904
	Insurance financing and accrued interest expenses			611		598
	Legal expenses			573		268
	Manufacturing expenses			225		247
	Rebates and royalties			186		—
	Other			1,479		1,891
			$	9,469	$	10,209

Leases

Leases	12 Months Ended
	Dec. 31, 2013
Leases	'
	7	Leases
	Lease Agreements
	We lease our office space under operating leases for our U.S. and European offices. Rent expense amounted to $2.0 million, $2.7 million and $1.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. Rent expense is net of sublease income and amounts offset to excess facilities charges.
	In January 2012, we entered into an agreement with Selig Holdings Company LLC, or Selig, to lease approximately 66,000 square feet of office space in Seattle, Washington. The term of this lease is for a period of 120 months, which commenced on May 1, 2012. We have two five-year options to extend the term of the lease at a market rate determined according to the lease. No rent payments were due during the first five months of the lease term. The initial rent amount is based on $27.00 per square foot per annum for the remainder of the first 12 months, with rent increasing three percent over the prior year’s rent amount for each year thereafter for the duration of the lease. In addition, we were provided an allowance of $3.3 million for certain tenant improvements made by us. As of December 31, 2012, we had a receivable of $1.5 million included in prepaid expenses and other current assets related to the unpaid portion of incentives for tenant improvements owed to us by Selig. We had no receivable related to incentives for tenant improvements as of December 31, 2013.
	Future Minimum Lease Payments
	Future minimum lease commitments for non-cancelable operating leases at December 31, 2013 are as follows (in thousands):
			Operating
			Leases
	2014		$	2,534
	2015			2,508
	2016			2,220
	2017			2,280
	2018			2,341
	Thereafter			8,264
	Total minimum lease commitments		$	20,147
	Liability for Excess Facilities
	During the year ended December 31, 2005, we reduced our workforce in the United States and Europe. In conjunction with this reduction in force, we vacated a portion of our laboratory and office facilities and recorded excess facilities charges. Charges for excess facilities relate to our lease obligation for excess laboratory and office space in the United States that we vacated as a result of the restructuring plan. We recorded these restructuring charges when we ceased using this space.
	During the year ended December 31, 2010, we recorded an additional liability of $1.5 million for excess facilities under an operating lease upon vacating a portion of our corporate office space. The related charge for excess facilities was recorded as a component of rent expense, which is included in research and development and selling, general and administrative expenses for the year ended December 31, 2010.
	The following table summarizes the changes in the liability for excess facilities during the years ended December 31, 2012 and 2011 (in thousands):
			2005			2010			Total Excess
			Activities			Activities			Facilities
									Liability
	Balance at January 1, 2011		$	550		$	1,410		$	1,960
	Adjustments			40			102			142
	Payments			(375	)		(982	)		(1,357	)
	Balance at December 31, 2011			215			530			745
	Adjustments			(32	)		(62	)		(94	)
	Payments			(183	)		(468	)		(651	)
	Balance at December 31, 2012		$	—		$	—		$	—
	We will periodically evaluate our existing needs and other future commitments to determine whether we should record additional excess facilities charges or adjustments to such charges.

Other_Liabilities

Other Liabilities	12 Months Ended
	Dec. 31, 2013
Other Liabilities	'
	8	Other Liabilities
	Other liabilities consisted of the following as of December 31, 2013 and 2012 (in thousands):
			2013			2012
	Deferred rent		$	4,769		$	5,003
	Other long-term obligations			1,281			31
				6,050			5,034
	Less: other current liabilities			(393	)		(393	)
			$	5,657		$	4,641
	The balance of deferred rent as of December 31, 2013 and 2012 relates to incentives for rent holidays and leasehold improvements associated with our operating lease for office space as discussed in Note 7, Leases. The balance of other long-term obligations includes a fee in the amount of $1.3 million payable to Hercules Technology Growth Capital. See Note 10, Long-term Debt, for additional information.

Convertible_Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2013
Convertible Notes	'
	9	Convertible Notes
	The following tables summarize the changes in the principal balances of our convertible notes during the year ended December 31, 2011:
			Balance at		Exchanged		Matured			Balance at
			January 1,							December 31,
			2011							2011
	7.5% convertible senior notes		$	10,250	$	—	$	(10,250	)	$	—
	5.75% convertible senior notes			10,913		—		(10,913	)		—
	Total		$	21,163	$	—	$	(21,163	)	$	—

Longterm_Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2013
Long-term Debt	'
	10	Long-term Debt
	In March 2013, we entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc., or HTGC, for a senior secured term loan of up to $15.0 million. The first $10.0 million was funded in March 2013, and we exercised our option to borrow an additional $5.0 million in December 2013. The interest rate on the term loan floats at a rate per annum equal to 12.25% plus the amount by which the prime rate exceeds 3.25%. The term loan is repayable in 30 equal monthly installments of principal and interest (mortgage style) over 42 months, including an initial interest-only period of 12 months after closing. The loan obligations are secured by a first priority security interest on substantially all of our personal property except our intellectual property and subject to certain other exceptions. We paid a facility charge of $150,000 at closing and a fee in the amount of $1.3 million is payable to HTGC on the date on which the term loan is paid or becomes due and payable in full. We recorded debt discount of $2.1 million, of which $1.7 million is unamortized as of December 31, 2013. We recorded issuance costs of $0.3 million, of which $0.3 million is unamortized as of December 31, 2013.
	In addition, we issued a warrant to HTGC to purchase shares of common stock. The warrant is exercisable for five years from the date of issuance for 0.7 million shares of common stock. The initial exercise price of the warrant is $1.1045 per share of common stock. The exercise price and number of shares of common stock issuable upon exercise are subject to antidilution adjustments in certain events, including if within 12 months after closing the Company issues shares of common stock or securities that are exercisable or convertible into shares of common stock in transactions not registered under the Securities Act of 1933, as amended, at an effective price per share of common stock that is less than the exercise price of the warrant, then the exercise price shall automatically be reduced to equal the price per share of common stock in such transaction and the number of shares will be increased proportionately. Since the warrant did not meet the considerations necessary for equity classification in the applicable authoritative guidance, we determined the warrant is a liability instrument that is marked to fair value with changes in fair value recognized through earnings at each reporting period. As of the issuance date and December 31, 2013, we estimated the fair value of the warrant to be $0.5 million and $1.0 million, respectively. We classified the warrant as Level 2 in the fair value hierarchy as the significant inputs used in determining fair value are considered observable market data. In January 2014, all of the warrant was exercised into 0.5 million shares of common stock via cashless exercise.

Preferred_Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2013
Preferred Stock	'
	11	Preferred Stock
	Prior to the effective date of the Stock Splits, we completed several preferred stock transactions during the years 2011 and 2012, each of which is described below. All outstanding shares of the preferred stock issued in these transactions converted to common stock or were redeemed, in each case, prior to the effective date of the Stock Splits. Accordingly, for purposes of the descriptions of these transactions included in this Note 11, Preferred Stock, the number of shares of preferred stock issued, converted and redeemed and the initial stated value of shares of preferred stock issued are not adjusted to reflect the Stock Splits. However, the number of shares of common stock issued upon conversion of the preferred stock, the conversion price of common stock issued upon conversion, the exercise prices of warrants issued and the number of shares of common stock issued or issuable upon exercise or exchange of the warrants in these transactions are adjusted to reflect the Stock Splits.
	Series 8 and 9 Preferred Stock
	In January 2011, we issued to an institutional investor, or the Investor, 25,000 shares of Series 8 non-convertible preferred stock, or Series 8 Preferred Stock, warrants to purchase up to 0.8 million shares of our common stock and an additional investment right to purchase up to 25,000 shares of Series 9 convertible preferred stock, or Series 9 Preferred Stock, for an aggregate offering price of $25.0 million. The aggregate offering price was reduced by a 5% commitment fee retained by the Investor for total gross proceeds received of $23.7 million. We allocated the proceeds on a relative fair value basis, of which $18.5 million, $1.3 million and $3.9 million was allocated to the Series 8 Preferred Stock, warrants and additional investment right, respectively. Issuance costs related to this transaction were approximately $0.5 million.
	The shares of Series 8 Preferred Stock accrued annual dividends at the rate of 10% from the date of issuance, payable in the form of additional shares of Series 8 Preferred Stock. The shares of Series 8 Preferred Stock were redeemable by the Company at any time after issuance, either in cash or by offset against recourse notes fully secured with marketable securities, or Recourse Notes, which were issued by the Investor to the Company in connection with the exercise of the warrants and the additional investment right as discussed below.
	Each warrant had an exercise price of $11.634 per share of our common stock. The warrants were exercisable immediately and had an expiration date in January 2013. The holder of the warrants had the option to pay the exercise price for the warrant either in cash or through the issuance of Recourse Notes to the Company. The Investor exercised all of the warrants to purchase 0.8 million shares of common stock for a total of $8.8 million through the issuance of Recourse Notes by the Investor to the Company.
	Each additional investment right had an exercise price of $1,000 per share of Series 9 Preferred Stock. The additional investment right was exercisable immediately upon issuance and had an expiration date in February 2011. The holder of the additional investment right had the option to pay the exercise price in cash or through issuance of Recourse Notes to the Company. The Investor exercised the entire additional investment right to purchase 25,000 shares of Series 9 Preferred Stock for a total of $25.0 million through the issuance of Recourse Notes by the Investor to the Company. The Investor also elected to convert all 25,000 shares of Series 9 Preferred Stock into 2.1 million shares of our common stock at a conversion price of $11.634 per share.
	In March 2011, we redeemed all 25,000 outstanding shares of Series 8 Preferred Stock (plus accrued dividends). Each share of Series 8 Preferred Stock (plus accrued dividends) was offset by $1,350 principal amount of Recourse Notes (plus accrued interest), regardless of the issuance date of the shares of Series 8 Preferred Stock and Recourse Notes. We recognized $0.4 million in accrued dividends on the Series 8 Preferred Stock and $0.1 million accrued interest on the Recourse Notes through the redemption date, both of which are included in dividends and deemed dividends on preferred stock for the year ended December 31, 2011. Additionally, we recognized $15.5 million in dividends and deemed dividends on preferred stock for the year ended December 31, 2011 upon redemption of the Series 8 Preferred Stock equal to the difference between the $33.9 million principal balance of Recourse Notes, including accrued interest, and $18.4 million carrying amount of Series 8 Preferred Stock, including accrued dividends.
	Series 10 and 11 Preferred Stock
	In February 2011, we issued to the Investor 24,957 shares of Series 10 non-convertible preferred stock, or Series 10 Preferred Stock, warrants to purchase up to 0.9 million shares of our common stock and an additional investment right to purchase up to 24,957 shares of Series 11 convertible preferred stock, or Series 11 Preferred Stock, for an aggregate offering price of approximately $25.0 million. The aggregate offering price was reduced by a 5% commitment fee retained by the Investor for total gross proceeds received of $23.7 million. We allocated the proceeds on a relative fair value basis, of which $18.5 million, $1.3 million and $3.9 million was allocated to the Series 10 Preferred Stock, warrants and additional investment right, respectively. Issuance costs related to this transaction were approximately $0.3 million.
	The shares of Series 10 Preferred Stock accrued annual dividends at the rate of 10% from the date of issuance, payable in the form of additional shares of Series 10 Preferred Stock. The shares of Series 10 Preferred Stock were redeemable by the Company at any time after issuance, either in cash or by offset against Recourse Notes, which were issued by the Investor to the Company in connection with the exercise of the warrants and the additional investment right as discussed below.
	Each warrant had an initial exercise price of $10.11 per share of our common stock. The warrants were exercisable immediately and had an expiration date in February 2013. The holder of the warrants had the option to pay the exercise price for the warrant either in cash or through the issuance of Recourse Notes to the Company. The Investor exercised all of the warrants to purchase 0.9 million shares of our common stock for a total of $8.7 million through the issuance of Recourse Notes by the Investor to the Company.
	Each additional investment right had an exercise price of $1,000 per share of Series 11 Preferred Stock. The additional investment right was exercisable immediately upon issuance and had an expiration date in March 2011. The holder of the additional investment right had the option to pay the exercise price in cash or through issuance of Recourse Notes to the Company. The Investor exercised the entire additional investment right to purchase 24,957 shares of Series 11 Preferred Stock for a total of approximately $25.0 million through the issuance of Recourse Notes by the Investor to the Company. The Investor also elected to convert all 24,957 shares of Series 11 Preferred Stock into 2.5 million shares of our common stock at a conversion price of $10.11 per share.
	In March 2011, we redeemed all 24,957 outstanding shares of Series 10 Preferred Stock (plus accrued dividends). Each share of Series 10 Preferred Stock (plus accrued dividends) was offset by $1,350 principal amount of Recourse Notes (plus accrued interest), regardless of the issuance date of the shares of Series 10 Preferred Stock and Recourse Notes. We recognized $0.1 million in accrued dividends on the Series 10 Preferred Stock and $41,000 accrued interest on the Recourse Notes through the redemption date, both of which are included in dividends and deemed dividends on preferred stock for the year ended December 31, 2011. Additionally, we recognized $15.4 million in dividends and deemed dividends on preferred stock for the year ended December 31, 2011 upon redemption of the Series 10 Preferred Stock equal to the difference between the $33.7 million principal balance of Recourse Notes, including accrued interest, and $18.3 million carrying amount of Series 10 Preferred Stock, including accrued dividends.
	Series 12 Convertible Preferred Stock
	In May 2011, we issued 15,972 shares of our Series 12 convertible preferred stock, or Series 12 Preferred Stock, and warrants to purchase up to 0.6 million shares of our common stock for gross proceeds of $16.0 million. Issuance costs related to this transaction were $1.2 million, including the fair value of the placement agent warrants discussed below. Each warrant has an exercise price of $12.00 per share of our common stock and expires in May 2016. We estimated the $4.1 million fair value of the warrants using the Black-Scholes pricing model. For the year ended December 31, 2011, we recognized $5.5 million in dividends and deemed dividends on preferred stock related to the beneficial conversion feature on our Series 12 Preferred Stock. In May 2011, all 15,972 shares of our Series 12 Preferred Stock were converted into 1.5 million shares of our common stock at a conversion price of $10.50 per share. As of December 31, 2013, warrants to purchase 0.6 million shares of our common stock remained outstanding.
	In connection with this offering, we also issued warrants to purchase up to 30,423 shares of our common stock to the placement agent, which were estimated to have a fair value of $0.2 million using the Black-Scholes pricing model. These warrants have an exercise price of $13.125 per share and expire in May 2016. As of December 31, 2013, warrants to purchase up to 30,423 shares of our common stock issued to the placement agent remained outstanding.
	Series 13 Convertible Preferred Stock
	In July 2011, we issued 30,000 shares of our Series 13 convertible preferred stock, or Series 13 Preferred Stock, and warrants to purchase up to 1.8 million shares of our common stock for gross proceeds of $30.0 million. Issuance costs related to this transaction were $2.5 million, including the fair value of the warrants issued to the placement agent and financial advisor discussed below. Each warrant has an exercise price of $10.75 per share of our common stock, was exercisable beginning six months and one day from the date of issuance and expires in July 2016. We estimated the $8.4 million fair value of the warrants using the Black-Scholes pricing model. For the year ended December 31, 2011, we recognized $13.0 million in dividends and deemed dividends on preferred stock related to the beneficial conversion feature on our Series 13 Preferred Stock. In July 2011, all 30,000 shares of our Series 13 Preferred Stock were converted into 3.5 million shares of our common stock at a conversion price of $8.50 per share. As of December 31, 2013, warrants to purchase up to 1.8 million shares of our common stock remained outstanding.
	In connection with this offering, we also issued warrants to purchase up to 70,588 shares of our common stock to the placement agent, which were estimated to have a fair value of $0.3 million using the Black-Scholes pricing model, and warrants to purchase up to 35,294 shares of our common stock to the financial advisor as partial compensation for its services in connection with this offering, which were estimated to have a fair value of $0.2 million using the Black-Scholes pricing model. These warrants have an exercise price of $12.25 per share, are exercisable beginning six months and one day from the date of issuance and expire in July 2016. As of December 31, 2013, warrants to purchase up to 70,588 and 35,294 shares of our common stock issued to the placement agent and financial advisor, respectively, remained outstanding.
	Series 14 Convertible Preferred Stock
	In December 2011, we issued 20,000 shares of our Series 14 convertible preferred stock, or Series 14 Preferred Stock, and warrants to purchase up to 1.4 million shares of our common stock for gross proceeds of $20.0 million. Issuance costs related to this transaction were $1.6 million, including the fair value of warrants issued to the placement agent and financial advisor discussed below. Each warrant has an exercise price of $7.25 per share of our common stock, was exercisable beginning six months and one day from the date of issuance and expires in December 2016. We estimated the $4.9 million fair value of the warrants using the Black-Scholes pricing model. For the year ended December 31, 2011, we recognized $8.9 million in dividends and deemed dividends on preferred stock related to the beneficial conversion feature on our Series 14 Preferred Stock. In December 2011, 10,000 shares of Series 14 Preferred Stock were converted into 1.7 million shares of our common stock at a conversion price of $5.75 per share. In January 2012, the remaining 10,000 shares of Series 14 Preferred Stock automatically converted into 1.7 million shares of our common stock at a conversion price of $5.75 per share pursuant to the terms of the Series 14 Preferred Stock. As of December 31, 2013, warrants to purchase up to 1.4 million shares of our common stock remained outstanding.
	In connection with this offering, we also issued warrants to purchase up to 69,566 shares of our common stock to the placement agent, which were estimated to have a fair value of $0.2 million using the Black-Scholes pricing model, and warrants to purchase up to 34,783 shares of our common stock to the financial advisor as partial compensation for its services in connection with this offering, which were estimated to have a fair value of $0.1 million using the Black-Scholes pricing model. These warrants have an exercise price of $8.625 per share, were exercisable beginning six months and one day from the date of issuance and expire in December 2016. As of December 31, 2013, warrants to purchase up to 69,566 and 34,783 shares of our common stock issued to the placement agent and financial advisor, respectively, remained outstanding.
	Series 15-1 Preferred Stock
	In May 2012, we issued 20,000 shares of our Series 15 convertible preferred stock, or Series 15-1 Preferred Stock, and a warrant to purchase up to 2.7 million shares of our common stock, or Series 15-1 Warrant, for gross proceeds of $20.0 million. Issuance costs related to this transaction were $1.3 million.
	Each share of our Series 15-1 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series 15-1 Preferred Stock, plus any accrued and unpaid dividends before the holders of our common stock or any other junior securities receive any payments upon such liquidation. The Series 15-1 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on our common stock or any pari passu or junior securities and had no voting rights except as otherwise expressly provided in our amended and restated articles of incorporation or as otherwise required by law. For the year ended December 31, 2012, we recognized $8.5 million in dividends and deemed dividends on preferred stock related to the beneficial conversion feature on our Series 15-1 Preferred Stock. In May 2012, all 20,000 shares of our Series 15-1 Preferred Stock were converted into 4.0 million shares of our common stock at a conversion price of $5.00 per share.
	The Series 15-1 Warrant had an exercise price of $5.46 per share of our common stock and had an expiration date in May 2017. The Series 15-1 Warrant contained a provision that if the price per share of our common stock was less than the exercise price of the warrant at any time while the warrant is outstanding, the warrant may be exchanged for shares of our common stock based on an exchange value derived from a specified Black-Scholes value formula, or the Exchange Value, subject to certain limitations. Upon issuance, we estimated the fair value of the Series 15-1 Warrant to be approximately $10.3 million using the Black-Scholes pricing model. In September 2012, the holder elected to exchange a portion of the Series 15-1 Warrant to purchase 1.3 million shares with an Exchange Value of $5.0 million. We elected to issue 2.8 million shares of our common stock as payment for the Exchange Value. In November 2012, the holder elected to exchange the remaining portion of the Series 15-1 Warrant to purchase 1.4 million shares of our common stock with an Exchange Value of $5.4 million. We elected to issue 4.1 million shares of our common stock as payment for the Exchange Value.
	Series 15-2 Preferred Stock
	In July 2012, we issued 15,000 shares of our Series 15 convertible preferred stock, or Series 15-2 Preferred Stock, and a warrant to purchase up to 3.4 million shares of our common stock, or Series 15-2 Warrant, for gross proceeds of $15.0 million. Issuance costs related to this transaction were $0.8 million.
	Each share of our Series 15-2 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series 15-2 Preferred Stock, plus any accrued and unpaid dividends before the holders of our common stock or any other junior securities receive any payments upon such liquidation. The Series 15-2 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on our common stock or any pari passu or junior securities and had no voting rights except as otherwise expressly provided in our amended and restated articles of incorporation or as otherwise required by law. In July 2012, all 15,000 shares of Series 15-2 Preferred Stock were converted into 5.0 million shares of our common stock at a conversion price of $2.97475 per share. For the year ended December 31, 2012, we recognized $5.0 million in dividends and deemed dividends on preferred stock related to the beneficial conversion feature on our Series 15-2 Preferred Stock.
	The Series 15-2 Warrant had substantially the same features as the Series 15-1 Warrant described above, with the exception of the exercise price of $3.0672 per share of common stock and expiration date of July 2017. Upon issuance, we estimated the fair value of the Series 15-2 Warrant to be approximately $7.2 million using the Black-Scholes pricing model. In September 2012, the holder elected to exchange the Series 15-2 Warrant to purchase 3.4 million shares of our common stock with an Exchange Value of $7.4 million. We elected to issue 2.9 million shares of common stock to the holder as payment for the Exchange Value of the Series 15-2 Warrant.
	Series 17 Preferred Stock
	In October 2012, we issued 60,000 shares of our Series 17 convertible preferred stock, or Series 17 Preferred Stock, in an underwritten public offering for gross proceeds of $60.0 million, before deducting underwriting commissions and discounts and other offering costs. Issuance costs related to this transaction were $5.5 million, including $3.9 million in underwriting commissions and discounts.
	Each share of Series 17 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the stated value of $1,000 per share plus any accrued and unpaid dividends before the holders of our common stock or any other junior securities receive any payments upon such liquidation. The holders of Series 17 Preferred Stock were not entitled to receive dividends except to share in any dividends actually paid on shares of our common stock or other junior securities and had no voting rights except as otherwise expressly provided in our amended and restated articles of incorporation or as otherwise required by law. For the year ended December 31, 2012, we recognized $0.4 million in dividends and deemed dividends on preferred stock related to the beneficial conversion feature on our Series 17 Preferred Stock and all 60,000 shares of Series 17 Preferred Stock were converted into 42.9 million shares of our common stock at a conversion price of $1.40 per share.
	Series 18 Preferred Stock
	In September 2013, we issued 15,000 shares of Series 18 preferred stock, or Series 18 Preferred Stock, for gross proceeds of $15.0 million in a registered direct offering. Issuance costs related to this transaction were $0.1 million. Each share of Series 18 Preferred Stock was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series 18 Preferred Stock, plus any accrued and unpaid dividends, before the holders of our common stock or any other junior securities receive any payments upon such liquidation. The Series 18 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series 18 Preferred Stock had no voting rights except as otherwise expressly provided in the amended articles or as otherwise required by law. For the year ended December 31, 2013, we recognized $6.9 million in dividends and deemed dividends on preferred stock related to the beneficial conversion feature on our Series 18 Preferred Stock. In September 2013, all 15,000 shares of Series 18 preferred stock were converted into 15.0 million shares of common stock at a conversion price of $1.00 per share.
	Series 19 Preferred Stock
	See Note 14, Collaboration, Licensing and Milestone Agreements—Baxter, for information concerning our issuance of Series 19 Preferred Stock.

Common_Stock

Common Stock	12 Months Ended
	Dec. 31, 2013
Common Stock	'
	12	Common Stock
	Common Stock Reserved
	A summary of common stock reserved for issuance is as follows as of December 31, 2013 (in thousands):
	Equity incentive plans		10,094
	Common stock purchase warrants		7,697
	Employee stock purchase plan		38
			17,829
	Warrants
	Warrants to purchase up to 0.1 million shares of our common stock, issued in connection with the issuance of our Series 1 Preferred Stock in April 2009, or Class B Warrants, were outstanding as of December 31, 2013. The Class B Warrants have an exercise of $12.30 per share of common stock and expire in October 2014. We classified the Class B Warrants as mezzanine equity as they include a redemption feature that may be triggered upon certain fundamental transactions that are outside of our control.
	Warrants to purchase up to 5,000 shares of common stock, issued to the placement agent in connection with our Series 1 Preferred Stock financing in April 2009, were outstanding as of December 31, 2013. These warrants have an exercise price of $13.50 per share and expire in October 2014. These warrants are classified as mezzanine equity due to the same redemption feature of the Class B warrants as described above.
	Warrants to purchase up to 0.2 million shares of our common stock, issued in connection with our registered offering of common stock in May 2009, were outstanding as of December 31, 2013. These warrants have an exercise price of $42.00 per share and expire in May 2014.
	Warrants to purchase up to 10,667 shares of our common stock, issued to the placement agent in connection with the registered offering of common stock in May 2009, were outstanding as of December 31, 2013. These warrants have an exercise price of $46.875 per share and expire in November 2014.
	Warrants to purchase up to 19,556 shares of our common stock, issued to the underwriter of our public offering of common stock in July 2009, were outstanding as of December 31, 2013. These warrants have an exercise price of $51.00 per share and expire in April 2014.
	See Note 10, Long-term Debt, and Note 11, Preferred Stock, for additional information concerning our warrants.

Other_Comprehensive_Loss

Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2013
Other Comprehensive Loss	'
	13	Other Comprehensive Loss
	Total accumulated other comprehensive loss consisted of the following (in thousands):
			Net Unrealized			Foreign			Accumulated
			Loss on Securities			Currency			Other
			Available-For-Sale			Translation			Comprehensive
						Adjustments			Loss
	December 31, 2012		$	(235	)	$	(8,038	)	$	(8,273	)
	Current period other comprehensive gain (loss)			(187	)		31			(156	)
	December 31, 2013		$	(422	)	$	(8,007	)	$	(8,429	)

Collaboration_Licensing_and_Mi

Collaboration, Licensing and Milestone Agreements	12 Months Ended
	Dec. 31, 2013
Collaboration, Licensing and Milestone Agreements	'
	14	Collaboration, Licensing and Milestone Agreements
	Baxter
	In November 2013, we entered into a Development, Commercialization and License agreement (the “Agreement”) with Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA (collectively, “Baxter”) for the development and commercialization of pacritinib (the “Compound”) for use in oncology and potentially additional therapeutic areas. Under the Agreement, we granted to Baxter an exclusive, worldwide (subject to our certain co-promotion rights in the U.S.), royalty-bearing, non-transferable, and (under certain circumstances outside of the U.S.) sub-licensable license to its know-how and patents relating to the Compound. We received an upfront payment of $60.0 million upon execution of the Agreement, which included an equity investment of $30 million to acquire our Series 19 Preferred Stock as discussed below.
	Under the Agreement, we may receive potential clinical, regulatory and commercial launch milestone payments of up to $112.0 million and potential additional sales-based milestone payments of up to $190.0 million. We have determined that all of the sales-based milestone payments are contingent consideration and will be accounted for as revenue in the period in which the respective revenue recognition criteria are met. We have also determined that all of the clinical, regulatory and commercial launch milestones are substantive and will be recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.
	Under the Agreement, the Company and Baxter will jointly commercialize and share profits and losses on sales of the Compound in the U.S. Outside the U.S., the Company is also eligible to receive tiered high single digit to mid-teen percentage royalties based on net sales for myelofibrosis, and higher double-digit royalties for other indications, subject to reduction by up to 50% if (i) Baxter is required to obtain additional third party licenses, on which it is obligated to pay royalties, to fulfill its obligations under the Agreement, and (ii) in any jurisdiction where there is no longer either regulatory exclusivity or patent protection.
	Under the Agreement, the Company is responsible for all development costs incurred prior to January 1, 2014 as well as approximately up to $96.0 million on or after January 1, 2014 for U.S. and E.U. development costs, subject to potential upward or downward adjustment in certain circumstances. All development costs exceeding such threshold will generally be shared as follows: (i) costs generally applicable worldwide will be shared 75% to Baxter and 25% to the Company, (ii) costs applicable to territories exclusive to Baxter will be 100% borne by Baxter and (iii) costs applicable exclusively to co-promotion in the U.S. will be shared equally between the parties, subject to certain exceptions.
	We record the development cost reimbursements received from Baxter as license and contract revenue in the statements of operations, and we record the full amount of development costs as research and development expense.
	Pursuant to the accounting guidance under ASC 605-25 Revenue Recognition – Multiple-Element Arrangements, we have determined that the following non-contingent deliverables under the Agreement meet the criteria for separation and are therefore treated as separate units of accounting:
		•		a license from the Company to develop and commercialize the Compound worldwide (subject to certain co-promotion rights of the Company in the U.S.); and
		•		development services provided by the Company related to jointly agreed-upon development activities with cost sharing as discussed above.
	Both of the above non-contingent deliverables have no general right of return and are determined to have standalone values.
	The Agreement also requires Baxter and the Company to negotiate and enter into a Manufacturing and Supply Agreement, which will provide for the manufacture of the licensed products, with an option for Baxter to finish and package encapsulated bulk product, within 180 days of the Agreement. The Manufacturing and Supply Agreement is not considered as a deliverable at the inception of the arrangement because the critical terms such as pricing and quantities are not defined and delivery of the services will be dependent on successful clinical results that are uncertain.
	Also under the Agreement, joint commercialization, manufacturing, development and steering committees with representatives from the Company and Baxter will be established. We have considered whether our participation on the joint development committees may be a separate deliverable and determined that it does not represent a separate unit of accounting as the committee’s activities are primarily related to governance and oversight of development activities and are therefore combined with the development services. Our participation on the joint commercialization and manufacturing committees is also determined to be a non-deliverable.
	We have also considered whether our regulatory roles under the Agreement constitute a separate deliverable and determined that it should also be combined with the development services.
	The Agreement will expire when there is no longer any obligation for Baxter to pay royalties to us in any jurisdiction, at which time the licenses granted to Baxter will become perpetual and royalty-free. Either party may terminate the Agreement prior to expiration in certain circumstances. The Company may terminate the Agreement if Baxter has not undertaken requisite regulatory or commercialization efforts in the applicable countries and certain other conditions are met. Baxter may terminate the Agreement prior to expiration in certain circumstances including (i) in the event development costs for myelofibrosis for the period commencing January 1, 2014 are reasonably projected to exceed a specified threshold, (ii) as to some or all countries in the event of commercial failure of the licensed product or (iii) without cause following the one-year anniversary of the Agreement date, provided that such termination will have a lead-in period of six months before it becomes effective. Additionally, either party may terminate the Agreement in events of force majeure, or the other party’s uncured material breach or insolvency. In the event of a termination prior to the expiration date, rights in the Compound will revert to the Company.
	We allocated the fixed and determinable Agreement consideration of $30 million based on the percentage of the relative selling price of each unit of accounting. We estimated the selling price of the license using the income approach which values the license by discounting direct cash flow expected to be generated over the remaining life of the license, net of cash flow adjustments related to working capital. We estimated the selling price of the development services by discounting the estimated development expenditures to the date of arrangement which include internal estimates of personnel needed to perform the development services as well as third party costs for services and supplies. Of the $30 million Agreement consideration, $27.3 million was allocated to the license and $2.7 million was allocated to the development services.
	Because delivery of the license occurred upon the execution of the Agreement in November 2013 and the remaining revenue recognition criteria were met, all $27.3 million of the allocated arrangement consideration related to the license was recognized as revenue during the year ended December 31, 2013.
	The allocated amount of $2.7 million to the development services is expected to be recognized as development service revenue through approximately 2018, with majority of development services expected to be completed through approximately 2015, based on a proportional performance method, by which revenue is recognized in proportion to the development costs incurred. During the year ended December 31, 2013, $0.1 million was recognized as revenue, and the remaining $2.6 million was recorded as deferred revenue in the balance sheet as of December 31, 2013.
	License and contract revenue recognized in the statement of operations related to the Agreement were as follows (in thousands):
			Years ended December 31,
			2013		2012		2011
	License		$	27,275	$	—	$	—
	Development services			89		—		—
	License and contract revenue		$	27,364	$	—	$	—
	As of December 31, 2013, deferred revenue amounts related to the Agreement consisted of (in thousands):
			December 31,
			2013		2012
	Current portion of deferred revenue		$	1,010	$	—
	Deferred revenue, less current portion			1,626		—
	Total deferred revenue		$	2,636	$	—
	Concurrently with the execution of the Agreement, we issued 30,000 shares of Series 19 convertible preferred stock, no par value, or Series 19 Preferred Stock to Baxter for $30.0 million. Issuance costs related to this transaction were $0.2 million. Each share of Series 19 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the stated value of $1,000 per share plus any accrued and unpaid dividends before the holders of our common stock or any other junior securities receive any payments upon such liquidation. The holder of Series 19 Preferred Stock was not entitled to receive dividends except to share in any dividends actually paid on shares of our common stock or other junior securities and had no voting rights except as otherwise expressly provided in our amended and restated articles of incorporation or as otherwise required by law. For the year ended December 31, 2013, all 30,000 shares of Series 19 Preferred Stock were converted into 15,673,981 shares of our common stock at a conversion price of $1.914 per share. There was no beneficial conversion feature on Series 19 Preferred Stock.
	Novartis
	In January 2014, we entered into a Termination Agreement, or the Termination Agreement, with Novartis International Pharmaceutical Ltd., or Novartis, to reacquire the rights to PIXUVRI and Opaxio, or collectively, the Compounds, previously granted to Novartis under our License and Co-Development Agreement with Novartis entered into in September 2006, as amended, or the Original Agreement. Pursuant to the Termination Agreement, the Original Agreement was terminated in its entirety, other than certain customary provisions, including those pertaining to confidentiality and indemnification, which survive termination.
	Under the Termination Agreement, we agreed not to transfer, license, sublicense or otherwise grant rights with respect to intellectual property of the Compounds unless the transferee/licensee/sublicensee agrees to be bound by the terms of the Termination Agreement. We also agreed to provide potential payments to Novartis, including a percentage ranging from the low double-digits to the mid-teens, of any consideration received by us or our affiliates in connection with any transfer, license, sublicense or other grant of rights with respect to intellectual property of PIXUVRI or Opaxio, respectively; provided that such payments will not exceed certain prescribed ceilings in the low-single digit millions. Novartis is entitled to receive potential payments of up to $16.6 million upon the successful achievement of certain sales milestones of the Compounds. Novartis is also eligible to receive tiered low single-digit percentage royalty payments for the first several hundred million in annual net sales, and ten percent royalty payments thereafter based on annual net sales of each Compound, subject to reduction in the event generic drugs are introduced and sold by a third party, causing the sale of PIXUVRI or Opaxio to fall by a percentage in the high double-digits. To the extent we are required to pay royalties on net sales of Opaxio pursuant to the license agreement between us and PG-TXL Company, L.P., dated as of November 13, 1998, as amended, we may credit a percentage of the amount of such royalties paid to those payable to Novartis, subject to certain exceptions. Notwithstanding the foregoing, royalty payments for both PIXUVRI and Opaxio are subject to certain minimum floor percentages in the low single-digits.
	University of Vermont
	We entered into an agreement with the University of Vermont, or UVM Agreement, in March 1995, as amended in March 2000, which grants us an exclusive license, with the right to sublicense, for the rights to PIXUVRI, or the UVM Agreement. Pursuant to the UVM Agreement, we acquired the rights to make, have made, sell and use PIXUVRI. Pursuant to the UVM Agreement, we are obligated to make payments to UVM based on net sales. Our royalty payments range from low-single digits to mid-single digits as a percentage of net sales. The higher royalty rate is payable for net sales in countries where specified UVM licensed patents exist, or where we have obtained orphan drug protection, until such UVM patents or such protection no longer exists. For a period of ten years after first commercialization of PIXUVRI, the lower royalty rate is payable for net sales in such countries after expiration of the designated UVM patents or loss of orphan drug protection, and in all other countries without such specified UVM patents or orphan drug protection. Unless otherwise terminated, the term of the UVM Agreement continues for the life of the licensed patents in those countries in which a licensed patent exists, and continues for ten years after the first sale of PIXUVRI in those countries where no such patents exist. We may terminate the UVM Agreement, on a country-by-country basis or on a patent-by-patent basis, at any time upon advance written notice. UVM may terminate the UVM Agreement upon advance written notice in the event royalty payments are not made. In addition, either party may terminate the UVM Agreement (a) in the event of an uncured material breach of the UVM Agreement by the other party; or (b) in the event of bankruptcy of the other party.
	S*BIO Pte Ltd
	See Note 5, Acquisitions, for further information regarding the asset purchase agreement with S*BIO.
	Chroma Therapeutics, Ltd.
	We entered into an agreement with Chroma Therapeutics, Ltd., or Chroma, or the Chroma License Agreement, in March 2011 under which we have an exclusive license to certain technology and intellectual property controlled by Chroma to develop and commercialize the drug candidate, tosedostat, in North, Central and South America, or the Licensed Territory. Pursuant to the terms of the Chroma License Agreement, we paid Chroma an upfront fee of $5.0 million upon execution of the agreement. Research and development expense attributable to the Chroma License Agreement was $1.0 million, $2.8 million and $7.0 million for the years 2013, 2012 and 2011, respectively, of which $0.1 million and $0.2 million was included in accrued expenses as of December 31, 2013 and 2012, respectively. We will make a milestone payment of $5.0 million upon the initiation of the first pivotal trial. The Chroma License Agreement also includes additional development- and sales-based milestone payments related to acute myeloid leukemia, or AML, and certain other indications, up to a maximum amount of $209.0 million payable by us to Chroma if all development and sales milestones are achieved.
	Under the Chroma License Agreement, we are also required to pay Chroma royalties on net sales of tosedostat in any country within the Licensed Territory, commencing on the first commercial sale of tosedostat in any country in the Licensed Territory and continuing with respect to that country until the later of (a) the expiration date of the last patent claim covering tosedostat in that country, (b) the expiration of all regulatory exclusivity periods for tosedostat in that country or (c) ten years after the first commercial sale in that country. Royalty payments to Chroma are based on net sales volumes in any country within the Licensed Territory and range from the low- to mid-teens as a percentage of net sales.
	Under the Chroma License Agreement, we are also required to oversee and be responsible for performing the development operations and commercialization activities in the Licensed Territory and Chroma will oversee and be responsible for performing the development operations and commercialization activities worldwide except for the Licensed Territory. Development costs may not exceed $50.0 million for the first three years of the Chroma License Agreement unless agreed by the parties and we will be responsible for 75% of all development costs, while Chroma will be responsible for 25% of all development costs, subject to certain exceptions. Chroma is responsible for the manufacturing of tosedostat for development purposes in accordance with the terms of the manufacturing and supply agreement that we entered into with Chroma for our drug candidate tosedostat, which commenced on June 8, 2011.
	We have the option of obtaining a commercial supply of tosedostat from Chroma or from another manufacturer at our sole discretion in the Licensed Territory. The Chroma License Agreement may be terminated by us at our convenience upon 120 days’ written notice to Chroma. The Chroma License Agreement may also be terminated by either party following a material breach by the other party subject to notice and cure periods.
	By a letter dated July 18, 2012 Chroma notified us that Chroma alleges breaches under the Chroma License Agreement. Chroma asserts that we have not complied with the Chroma License Agreement because we made decisions with respect to the development of tosedostat without the approval of the joint committees to be established pursuant to the terms of the Chroma License Agreement, did not hold meetings of those committees and have not used diligent efforts in the development of tosedostat. We dispute Chroma’s allegations and intend to vigorously defend our development activities and judgments. In particular, we dispute Chroma’s lack of diligence claim based in part on the appropriateness of completing the ongoing Phase 2 combination trials prior to developing a Phase 3 trial design. In addition, we believe that Chroma has failed to comply with its antecedent obligations with respect to the joint committees and failed to demonstrate an ability to manufacture tosedostat to the required standards under the terms of the Chroma License Agreement. Under the Chroma License Agreement there is a 90 day cure period for any nonpayment default, which period shall be extended to 180 days if the party is using efforts to cure. A party may terminate the Chroma License Agreement for a material breach only after arbitration in accordance with the terms of the Chroma License Agreement.
	Effective September 25, 2012, we and Chroma entered into a standstill with respect to the parties’ respective claims under the Chroma License Agreement, but otherwise reserving the parties’ respective rights as of the commencement of the standstill period. The standstill was extended through June 25, 2013, but has not been renewed by the parties.
	Gynecologic Oncology Group
	We entered into an agreement with the Gynecologic Oncology Group, or GOG, in March 2004, as amended in August 2008 and August 2013, related to the GOG-0212 trial of Opaxio in patients with ovarian cancer, which the GOG is conducting. We recorded a $0.9 million payment due to the GOG based on the 1,100 patient enrollment milestone achieved in the third quarter of 2013, which is included in accounts payable as of December 31, 2013. In addition, we may be required to pay up to $1.2 million upon the attainment of certain milestones, as well as other fees under certain circumstances, of which $0.7 million is included in accrued expenses as of December 31, 2013. In January 2014, we were informed by the GOG that enrollment in the trial had been completed, with 1,150 patients enrolled.
	PG-TXL
	In November 1998, we entered into an agreement with PG-TXL Company, L.P., or PG-TXL, as amended in February 2006, which grants us an exclusive worldwide license for the rights to Opaxio and to all potential uses of PG-TXL’s polymer technology, or the PG-TXL Agreement. Pursuant to the PG-TXL Agreement, we acquired the rights to research, develop, manufacture, market and sell anti-cancer drugs developed using this polymer technology. Pursuant to the PG-TXL Agreement, we are obligated to make payments to PG-TXL upon the achievement of certain development and regulatory milestones of up to $14.4 million. The timing of the remaining milestone payments under the PG-TXL Agreement is based on trial commencements and completions for compounds protected by PG-TXL license rights, and regulatory and marketing approval of those compounds by the FDA and the EMA. Additionally, we are required to make royalty payments to PG-TXL based on net sales. Our royalty payments range from low-single digits to mid-single digits as a percentage of net sales. Unless otherwise terminated, the term of the PG-TXL Agreement continues until no royalties are payable to PG-TXL. We may terminate the PG-TXL Agreement (i) upon advance written notice to PG-TXL in the event issues regarding the safety of the products licensed pursuant to the PG-TXL Agreement arise during development or clinical data obtained reveal a materially adverse tolerability profile for the licensed product in humans or (ii) for any reason upon advance written notice. In addition, either party may terminate the PG-TXL Agreement (a) upon advance written notice in the event certain license fee payments are not made; (b) in the event of an uncured material breach of the respective material obligations and conditions of the PG-TXL Agreement; or (c) in the event of liquidation or bankruptcy of a party.
	Nerviano Medical Sciences
	Under a license agreement entered into with Nerviano Medical Sciences, S.r.l. for brostallicin, we may be required to pay up to $80.0 million in milestone payments based on the achievement of certain product development results. Due to the early stage of development of brostallicin, we cannot make a determination that the milestone payments are reasonably likely to occur at this time.
	Cephalon
	Pursuant to an acquisition agreement entered into with Cephalon, Inc., or Cephalon, in June 2005, we have the right to receive up to $100.0 million in payments upon achievement of specified sales and development milestones related to TRISENOX. In November 2013, we received $5.0 million from Teva Pharmaceutical Industries Ltd., or Teva, upon the achievement of a worldwide net sales milestone of TRISENOX, which was included in license and contract revenue for the year ended December 31, 2013. TRISENOX was acquired from us by Cephalon. Cephalon was subsequently acquired by Teva. The achievement of the remaining milestones is uncertain at this time.
	Other Agreements
	We have several agreements with contract research organizations, third party manufacturers, and distributors which have duration greater than one year for the development and distribution of our products.

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2013
Share-Based Compensation	'
	15	Share-Based Compensation
	Share-Based Compensation Expense
	Share-based compensation expense for all share-based payment awards made to employees and directors is measured based on the grant-date fair value estimated in accordance with generally accepted accounting principles. We recognized share-based compensation using the straight-line, single-award method based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Share-based compensation is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met.
	For the years ended December 31, 2013, 2012 and 2011, we recognized share-based compensation expense due to the following types of awards (in thousands):
			2013			2012			2011
	Performance rights		$	1,165		$	2,358		$	—
	Restricted stock			5,906			5,180			4,850
	Options			1,995			400			167
	Total share-based compensation expense		$	9,066		$	7,938		$	5,017
	The following table summarizes share-based compensation expense for the years ended December 31, 2013, 2012 and 2011, which was allocated as follows (in thousands):
			2013			2012			2011
	Research and development		$	2,178		$	1,730		$	1,126
	Selling, general and administrative			6,888			6,208			3,891
	Total share-based compensation expense		$	9,066		$	7,938		$	5,017
	Share-based compensation had a $9.1 million, $7.9 million and $5.0 million effect on our net loss attributable to common shareholders, which resulted in a $(0.08), $(0.14) and $(0.15) effect on basic and diluted net loss per common share for the years ended December 31, 2013, 2012 and 2011, respectively. It had no effect on cash flows from operations or financing activities for the periods presented; however, during the years ended 2013, 2012 and 2011, we repurchased 200,000, 23,000 and 44,000 shares of our common stock totaling $0.2 million, $0.1 million and $0.4 million, respectively, for cash in connection with the vesting of employee restricted stock awards based on taxes owed by employees upon vesting of the awards.
	As of December 31, 2013, unrecognized compensation cost related to unvested stock options and time-based restricted stock awards amounted to $8.4 million, which will be recognized over the remaining weighted-average requisite service period of 1.1 years. The unrecognized compensation cost related to unvested options and restricted stock does not include the value of performance-based share awards.
	For the years ended December 31, 2013, 2012 and 2011, no tax benefits were attributed to the share-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.
	Stock Plan
	Pursuant to our 2007 Equity Incentive Plan, as amended and restated in April 2013, or the Plan, we may grant the following types of incentive awards: (1) stock options, including incentive stock options and non-qualified stock options, (2) stock appreciation rights, (3) restricted stock, (4) restricted stock units and (5) cash awards. The Plan is administered by the Compensation Committee of our Board of Directors, which has the discretion to determine the employees, consultants and directors who shall be granted incentive awards. Options expire 10 years from the date of grant, subject to the recipients continued service to the Company. As of December 31, 2013, 21.5 million shares were authorized for issuance, of which 5.6 million shares of common stock were available for future grants, under the Plan.
	Stock Options
	Fair value for employee stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:
			Year Ended December 31,
			2013			2012			2011
	Risk-free interest rate			1.4	%		0.8	%		0.9	%
	Expected dividend yield			None			None			None
	Expected life (in years)			5.3			4.7			4.5
	Volatility			102	%		88	%		97	%
	The risk-free interest rate used in the Black-Scholes valuation method is based on the implied yield currently available for U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid any dividends on our common stock and do not currently expect to do so in the future. The expected term of options represents the period that our options are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised options. Consideration was given to the contractual terms of our options, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry.
	Our stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of options calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. As we also recognize compensation expense for only the portion of options expected to vest, we apply estimated forfeiture rates that we derive from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, additional adjustments to compensation expense may be required in future periods.
	The following table summarizes stock option activity for all of our stock option plans:
			Options			Weighted			Weighted			Aggregate
						Average			Average			Intrinsic
						Exercise			Remaining			Value
						Price			Contractual			(Thousands)
									Term (Years)
	Outstanding at January 1, 2011 (17,000 exercisable)			34,000		$	744.74
	Granted			126,000		$	5.48
	Exercised			—		$	—
	Forfeited			(2,000	)	$	9.91
	Cancelled and expired			(2,000	)	$	6,740.99
	Outstanding at December 31, 2011 (59,000 exercisable)			156,000		$	90.07
	Granted			179,000		$	4.92
	Exercised			—		$	—
	Forfeited			(23,000	)	$	5.93
	Cancelled and expired			(5,000	)	$	886.13
	Outstanding at December 31, 2012 (105,000 exercisable)			307,000		$	33.72
	Granted			4,352,000		$	1.71
	Exercised			—		$	—
	Forfeited			(112,000	)	$	2.4
	Cancelled and expired			(28,000	)	$	133.72
	Outstanding at December 31, 2013			4,519,000		$	3.04			9.53		$	889
	Vested or expected to vest at December 31, 2013			4,241,404		$	3.12			9.53		$	842
	Exercisable at December 31, 2013			1,560,000		$	5.39			9.54		$	358
	The weighted average exercise price of options exercisable at December 31, 2012 and 2011 was $89.08 and $228.95, respectively. The weighted average grant-date fair value of options granted during 2013, 2012 and 2011 was $1.32, $3.28 and $3.93 per option, respectively.
	Restricted Stock
	We issued 6.4 million, 4.3 million and 1.7 million shares of restricted common stock in 2013, 2012 and 2011, respectively. The weighted average grant-date fair value of restricted shares issued during 2013, 2012 and 2011 was $1.21, $4.77 and $6.23, respectively. Additionally, 1.2 million, 0.9 million and 1.2 million shares of restricted stock were cancelled during 2013, 2012 and 2011, respectively.
	A summary of the status of nonvested restricted stock awards as of December 31, 2013 and changes during the period then ended, is presented below:
			Nonvested Shares			Weighted Average
						Grant-Date Fair Value
						Per Share
	Nonvested at December 31, 2012			3,322,000		$	5.26
	Issued			6,375,000		$	1.21
	Vested			(3,841,000	)	$	1.83
Forfeited			(1,168,000	)	$	3.7
Nonvested at December 31, 2013			4,688,000		$	2.95
The total fair value of restricted stock awards vested during the years ended December 31, 2013, 2012 and 2011 was $5.1 million, $3.4 million and $3.5 million, respectively.
Long-Term Performance Awards
In November 2011, we granted restricted stock units to our executive officers and directors that became effective on January 3, 2012, or the Long-Term Performance Awards (previously referred to as our 2012-2014 performance awards). The Long-Term Performance Awards vest upon milestone-based performance conditions. If one or more of the underlying performance-based conditions are timely achieved, the award recipient will be entitled to receive a number of shares of our common stock (subject to share limits of the Plan), determined by multiplying (i) the award percentage corresponding to that particular performance goal by (ii) the total number of outstanding shares of our common stock as of the date that the particular performance goal is achieved. In March 2013, certain performance criteria of the Long-Term Performance Awards were modified, two new performance goals were added, one goal was cancelled, and the expiration date was extended to December 31, 2015. The total award percentages related to all eight performance goals in effect as of December 31, 2013 are 7.0% and 2.7% of shares outstanding at the time the performance goals are achieved for the senior management and director participants, respectively. A portion of each of these awards was granted in the form of restricted shares of common stock issued on January 3, 2012.
The fair value of the Long-Term Performance Awards was estimated based on the average present value of the awards to be issued upon achievement of the performance conditions. The average present value was calculated based upon the expected date the shares of common stock underlying the performance awards will vest, or the event date, the expected stock price on the event date, and the expected shares outstanding as of the event date. The event date, stock price and the shares outstanding were estimated using a Monte Carlo simulation model, which is based on assumptions by management, including the likelihood of achieving the milestones and potential future financings.
In June 2012, our Board of Directors certified completion of the performance condition relating to approval of our marketing authorization application for PIXUVRI in the European Union and 0.4 million shares vested to our executive officers and directors. We recognized $1.1 million in share-based compensation upon satisfaction of this performance condition for the year ended December 31, 2012. Subsequently, unvested performance awards representing rights to receive approximately 0.9% and 2.3% of shares outstanding at the time the respective performance goals would have been achieved were forfeited upon separation of certain executive officers from us in 2013 and 2012, respectively.
We determined the Long-Term Performance Awards with market-based performance conditions have a grant-date fair value of $4.8 million. We determined the market-based performance condition had an incremental fair value of $0.8 million on the modification date in March 2013, which is being recognized in addition to the unrecognized grant-date fair value as of the modification date over the remaining estimated requisite service period. We recognized $1.2 million and $1.3 million in share based compensation expense related to the performance awards with market-based performance conditions for the years ended December 31, 2013 and 2012, respectively.
In January 2014, the expiration date of the Long-Term Performance Awards was extended to December 31, 2016, and two new performance criteria were added to the performance awards.
Nonemployee Share-Based Compensation
Share-based compensation expense for awards granted to nonemployees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of options and restricted stock awards granted to nonemployees is periodically remeasured as the underlying options or awards vest. The value of the instrument is amortized to expense over the vesting period with final valuation measured on the vesting date. As of December 31, 2013 and 2011 unvested nonemployee options to acquire approximately 157,000 and 2,000 shares of common stock were outstanding, respectively. Additionally, unvested nonemployee restricted stock awards totaled approximately 163,000 and 2,000 as of December 31, 2013 and 2011, respectively. As of December 31, 2012, all nonemployee options and restricted stock awards had vested. We recorded compensation expense of $310,000 and $58,000 in 2013 and 2011, respectively, and reversed previously recorded compensation expense of $1,000 in 2012 related to nonemployee stock options and restricted stock awards.
Employee Stock Purchase Plan
Under our 2007 Employee Stock Purchase Plan, as amended and restated in August 2009, or the Purchase Plan, eligible employees may purchase a limited number of shares of our common stock at 85% of the lower of the subscription date fair market value and the purchase date fair market value. There are two six-month offerings per year. Under the Purchase Plan, we issued approximately 3,000 shares to employees in each year ended December 31, 2013, 2012 and 2011. There are 50,833 shares of common stock authorized under the Purchase Plan and 38,631 shares are reserved for future purchases as of December 31, 2013.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2013
Employee Benefit Plans	'
	16	Employee Benefit Plans
	The Company’s U.S. employees participate in the Cell Therapeutics, Inc. 401(k) Plan whereby eligible employees may defer up to 80% of their compensation, up to the annual maximum allowed by the Internal Revenue Service. We may make discretionary matching contributions based on certain plan provisions. We recorded $0.2 million, $0.2 million and $0.1 million related to discretionary matching contributions during each of the years ended December 31, 2013, 2012 and 2011, respectively.

Shareholder_Rights_Plan

Shareholder Rights Plan	12 Months Ended
	Dec. 31, 2013
Shareholder Rights Plan	'
	17	Shareholder Rights Plan
	In December 2009, our Board of Directors approved and adopted a shareholder rights plan, or Rights Plan, in which one preferred stock purchase right was distributed for each common share held as of the close of business on January 7, 2010. Initially, the rights are not exercisable, and are attached to and trade with, all of the shares of CTI’s common stock outstanding as of, and issued subsequent to January 7, 2010. In 2012, our Board of Directors approved certain amendments to the Rights Plan.
	Each right, if and when it becomes exercisable, will entitle the holder to purchase a unit consisting of one ten-thousandth of a share of Series ZZ Junior Participating Cumulative Preferred Stock, no par value per share, at a cash exercise price of $8.00 per unit, subject to standard adjustment in the Rights Plan. The rights will separate from the common stock and become exercisable if a person or group acquires 20% or more of our common stock. Upon acquisition of 20% or more of our common stock, the Board could decide that each right (except those held by a 20% shareholder, which become null and void) would become exercisable entitling the holder to receive upon exercise, in lieu of a number of units of preferred stock, that number of shares of our common stock having a market value of two times the exercise price of the right. In certain circumstances, including if there are insufficient shares of our common stock to permit the exercise in full of the rights, the holder may receive units of preferred stock, other securities, cash or property, or any combination of the foregoing.
	In addition, if we are acquired in a merger or other business combination transaction, each holder of a right, except those rights held by a 20% shareholder which become null and void, would have the right to receive, upon exercise, common stock of the acquiring company having a market value equal to two times the exercise price of the right. The Board may redeem the rights for $0.0001 per right or terminate the Rights Plan at any time prior to an acquisition by a person or group holding 20% or more of our common stock. The Rights Plan will expire on December 3, 2015.

Customer_and_Geographic_Concen

Customer and Geographic Concentrations	12 Months Ended
	Dec. 31, 2013
Customer and Geographic Concentrations	'
	18	Customer and Geographic Concentrations
	We consider our operations to be a single operating segment focused on the development, acquisition and commercialization of novel treatments for cancer. Financial results of this reportable segment are presented in the accompanying consolidated financial statements.
	All sales of PIXUVRI during 2013 were in Europe. Product sales from PIXUVRI’s major customers as a percentage of total product sales were as follows:
			Year Ended
			December 31,
			2013
	Customer A			67	%
	Customer B			4	%
	Customer C			3	%
	The following table depicts long-lived assets based on the following geographic locations (in thousands):
			Year Ended December 31,
			2013			2012
	United States		$	5,336		$	6,570
	Europe			142			215
			$	5,478		$	6,785

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Net Loss Per Share	'
	19	Net Loss Per Share
	Basic and diluted net loss per share is calculated using the weighted average number of shares outstanding as follows (in thousands, except per share amounts):
			Year Ended December 31,
			2013			2012			2011
	Net loss attributable to common shareholders		$	(49,643	)	$	(115,275	)	$	(121,078	)
	Basic and diluted:
	Weighted average shares outstanding			119,042			62,021			35,790
	Less weighted average restricted shares outstanding			(4,847	)		(3,896	)		(1,496	)
	Shares used in calculation of basic and diluted net loss per common share			114,195			58,125			34,294
	Net loss per common share: Basic and diluted		$	(0.43	)	$	(1.98	)	$	(3.53	)
	Options, warrants, unvested restricted share awards and rights, convertible debt, and convertible preferred stock aggregating 15.4 million, 8.6 million and 10.2 million common share equivalents were not included in the calculation of diluted net loss per share as their effects on the calculation were anti-dilutive as of December 31, 2013, 2012 and 2011, respectively, prior to the application of the as-if converted method for convertible securities and the treasury stock method for other dilutive securities, such as options and warrants. These amounts do not include outstanding share-based awards with market- or performance-based vesting conditions.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
	20	Related Party Transactions
	In May 2007, we formed Aequus, a majority-owned subsidiary of which our ownership was approximately 61% as of December 31, 2013. We entered into a license agreement with Aequus whereby Aequus gained rights to our Genetic Polymer™ technology which Aequus will continue to develop. The Genetic Polymer technology may speed the manufacture, development, and commercialization of follow-on and novel protein-based therapeutics.
	In May 2007, we also entered into an agreement to fund Aequus in exchange for a convertible promissory note. The terms of the note provide that (i) interest accrues at a rate of 6% per annum until maturity, (ii) in the event the note balance is not paid on or before the maturity date, interest accrues at a rate of 10% per annum and (iii) prior to maturity, the note is convertible into a number of shares of Aequus equity securities equal to the quotient obtained by dividing (a) the outstanding balance of the note by (b) the price per share of the Aequus equity securities. The note matured and was due and payable in May 2012, although it has not yet been repaid. We are currently in negotiations with Aequus to, among other things, extend the maturity date of the note. In addition, we entered into a services agreement to provide certain administrative and research and development services to Aequus. The amounts charged for these services, if unpaid by Aequus within 30 days, will be considered additional principal advanced under the promissory note. We funded Aequus $1.5 million, $0.6 million and $0.6 million during the years ended December 31, 2013, 2012 and 2011, respectively, including amounts advanced in association with the services agreement. The Aequus note balance, including accrued interest, was approximately $5.8 million and $4.0 million as of December 31, 2013 and 2012, respectively. This intercompany balance was eliminated in consolidation.
	Our President and Chief Executive Officer, James A. Bianco, M.D., and our Executive Vice President, Global Medical Affairs and Translational Medicine, Jack W. Singer, M.D., are both minority shareholders of Aequus, each owning approximately 4.3% of the equity in Aequus as of December 31, 2013. Both Dr. Bianco and Dr. Singer are members of Aequus’ Board of Directors. Additionally, Frederick W. Telling, Ph.D., a member of our Board of Directors, owns approximately 1.3% of Aequus as of December 31, 2013 and is also a member of Aequus’ Board of Directors.

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2013
Legal Proceedings	'
	21	Legal Proceedings
	In August 2009, SICOR Società Italiana Corticosteroidi S.R.L., or Sicor, filed a lawsuit in the Court of Milan to obtain the Court’s assessment that we were bound to source the chemical compound, BBR2778, from Sicor according to the terms of a supply agreement executed between Sicor and Novuspharma S.p.A, or Novuspharma, a pharmaceutical company located in Italy, on October 4, 2002. We are the successor in interest to such agreement by virtue of our merger with Novuspharma in January 2004. Sicor alleged that the agreement was not terminated according to its terms. We asserted that the supply agreement in question was properly terminated and that we have no further obligation to comply with its terms. On December 30, 2013, the Court of Milan issued its decision and rejected all of Sicor’s claims; this proceeding has therefore concluded. The decision of the Court of Milan is subject to potential appeal.
	On December 10, 2009, CONSOB sent us a notice claiming, among other now resolved claims, violation of the provisions of Section 114, paragraph 1 of the Italian Legislative Decree no. 58/98 due to the asserted late disclosure of the contents of the opinion expressed by Stonefield Josephson, Inc., an independent registered public accounting firm, with respect to our 2008 financial statements. The sanction established by Section 193, paragraph 1 of the Italian Legislative Decree no. 58/98 for such violation could require us to pay a pecuniary administrative sanction amounting to between $7,000 and $689,000 upon conversion from euros as of December 31, 2013. Until CONSOB’s right is barred, CONSOB may, at any time, confirm the occurrence of the asserted violation and apply a pecuniary administrative sanction within the foregoing range. To date, we have not received any such notification.
	VAT Assessments
	The Italian Tax Authority, or ITA, issued notices of assessment to CTI (Europe) based on the ITA’s audit of CTI (Europe)’s VAT returns for the years 2003, 2005, 2006 and 2007 (collectively, the “VAT Assessments”). The ITA audits concluded that CTI (Europe) did not collect and remit VAT on certain invoices issued to non-Italian clients for services performed by CTI (Europe). We believe that the services invoiced were non-VAT taxable consultancy services and that the VAT returns are correct as originally filed. We are defending ourselves against the assessments both on procedural grounds and on the merits of the case. We received favorable rulings in 2012, which remain subject to further appeal, and our then remaining deposit for the VAT Assessments was refunded to us in January 2013. Due to the change of the position for the VAT Assessments, we reversed the entire reserve for VAT assessed as of December 31, 2012.
	In June 2013, the Regional Tax Court issued decision no. 119/50/13 in regards to the 2003 VAT assessment, which accepted the appeal of the ITA and reversed the previous decision of the Provincial Tax Court. We believe that such decision has not carefully taken into account our arguments and the documentation we filed, and we therefore plan to appeal such decision in front of the Supreme Court both on procedural grounds and on the merits of the case. In January 2014, we were notified that the ITA has requested partial payment of the 2003 VAT assessment in the amount of $593,000 upon conversion from euros as of December 31, 2013. We paid such amount in March 2014.
	If the final decisions of the Supreme Court for the VAT Assessments are unfavorable to us, we may incur up to $12.9 million in losses for the VAT amount assessed including penalties, interest and fees upon conversion from euros as of December 31, 2013.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
	22	Income Taxes
	We file income tax returns in the United States, Italy and the United Kingdom. A substantial part of our operations takes place in the State of Washington, which does not impose an income tax as that term is defined in ASC 740, Income Taxes. As such, our state income tax expense or benefit, if recognized, would be immaterial to our operations. We are not currently under examination by an income tax authority, nor have we been notified that an examination is contemplated.
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying values of assets and liabilities for financial reporting and income tax reporting in accordance with ASC 740. We have a valuation allowance equal to net deferred tax assets due to the uncertainty of realizing the benefits of the assets. Our valuation allowance increased $11.3 million, decreased $113.5 million and increased $3.6 million during 2013, 2012 and 2011, respectively.
	The reconciliation between our effective tax rate and the income tax rate as of December 31, 2013, 2012 and 2011 is as follows:
			2013			2012			2011
	Federal income tax rate			(34	%)		(34	%)		(34	%)
	Research and development tax credits			(3	)		—			(2	)
	I.R.C. Section 382 limited research and development tax credits			—			1			—
	Non-deductible debt/equity costs			—			—			1
	Non-deductible executive compensation			1			1			1
	I.R.C. Section 382 limited net operating losses			3			134			21
	Valuation allowance			27			(111	)		6
	Expired tax attribute carryforwards			—			7			7
	Foreign tax rate differential			6			1			—
	Other			—			1			—
	Net effective tax rate			—	%		—	%		—	%
	Significant components of our deferred tax assets and liabilities as of December 31, 2013 and 2012 were as follows (in thousands):
			2013			2012
	Deferred tax assets:
	Net operating loss carryforwards		$	49,777		$	34,655
	Capitalized research and development			31,046			36,303
	Research and development tax credit carryforwards			1,486			223
	Stock based compensation			12,097			10,813
	Intangible assets			10,518			11,336
	Depreciation and amortization			96			8
	Other deferred tax assets			3,062			3,621
	Total deferred tax assets			108,082			96,959
	Less valuation allowance			(107,271	)		(95,949	)
				811			1,010
	Deferred tax liabilities:
	GAAP adjustments on Novuspharma merger			(208	)		(208	)
	Deductions for tax in excess of financial statements			(603	)		(802	)
	Total deferred tax liabilities			(811	)		(1,010	)
	Net deferred tax assets		$	—		$	—
	Due to our equity financing transactions, and other owner shifts as defined in Internal Revenue Code Section 382 (the “Code”), we incurred “ownership changes” pursuant to the Code. These ownership changes trigger a limitation on our ability to utilize our net operating losses (NOL) and research and development credits against future income. We have obtained a private letter ruling (PLR) that determines the availability of the NOL after a 2007 ownership change.
	In October 2012, an “ownership change” occurred. The ownership change limits the utilization of certain tax attributes including the NOL. After the October 2012 ownership change the utilization of the NOL is limited to approximately $4.3 million annually. At December 2013, the gross NOL carryforward was approximately $1.0 billion. The annual NOL limitation will reduce the available NOL carryforward to approximately $146.4 million. The deferred tax asset and valuation allowance have been reduced accordingly.
	Effective January 1, 2007, we adopted the provisions of FASB Interpretation 48, Accounting for Uncertainty in Income Taxes, as codified in ASC 740-10, and we have analyzed filing positions in our tax returns for all open years. We are subject to United States federal and state, Italian and United Kingdom income taxes with varying statutes of limitations. Tax years from 1998 forward remain open to examination due to the carryover of net operating losses or tax credits. Our policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2013, we had no unrecognized tax benefits and therefore no accrued interest or penalties related to unrecognized tax benefits. We believe that our income tax filing positions reflected in the various tax returns are more-likely-than not to be sustained on audit and thus there are no anticipated adjustments that would result in a material change to our consolidated financial position, results of operations and cash flows. Therefore, no reserves for uncertain income tax positions have been recorded.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss or tax carryforward exists. FASB concluded that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset except in certain circumstances the unrecognized tax benefit should be presented as a liability and should not be combined with deferred tax assets. The amendment is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with early adoption permitted. The Company will adopt this standard in the first quarter of 2014 and does not expect the adoption of this standard to have an impact on its consolidated financial statements.

Unaudited_Quarterly_Data

Unaudited Quarterly Data	12 Months Ended
	Dec. 31, 2013
Unaudited Quarterly Data	'
	23	Unaudited Quarterly Data
	The following table presents summarized unaudited quarterly financial data (in thousands, except per share data):
			First			Second			Third			Fourth
			Quarter			Quarter			Quarter			Quarter
	2013
	Total revenues (1)		$	1,126		$	306		$	362		$	32,884
	Product sales, net			1,126			306			362			520
	Gross profit			1,071			270			349			487
	Operating costs and expenses			(19,553	)		(18,158	)		(15,942	)		(22,551	)
	Net income (loss) attributable to CTI			(19,384	)		(18,011	)		(15,544	)		10,196
	Net income (loss) attributable to CTI common shareholders			(19,384	)		(18,011	)		(22,444	)		10,196
	Net income (loss) per common share—basic			(0.18	)		(0.17	)		(0.20	)		0.08
	Net income (loss) per common share—diluted			(0.18	)		(0.17	)		(0.20	)		0.08
	2012
	Total revenues		$	—		$	—		$	—		$	—
	Product sales, net			—			—			—			—
	Gross profit			—			—			—			—
	Operating costs and expenses (2)			(18,098	)		(49,400	)		(15,149	)		(18,850	)
	Net loss attributable to CTI			(17,446	)		(50,138	)		(15,189	)		(18,601	)
	Net loss attributable to CTI common shareholders			(17,446	)		(58,596	)		(20,203	)		(19,030	)
	Net loss per common share—basic			(0.43	)		(1.38	)		(0.38	)		(0.20	)
	Net loss per common share—diluted			(0.43	)		(1.38	)		(0.38	)		(0.20	)
	-1	Total revenues for the fourth quarter of 2013 include $27.4 million of license and contract revenue recognized in connection with the collaboration agreement with Baxter in November 2013 and $5.0 million of license and contract revenue from Teva in November 2013 upon the achievement of a worldwide net sales milestone of TRISENOX. See Note 14, Collaboration, Licensing and Milestone Agreements, for additional information.
	-2	Operating costs and expenses for the second quarter of 2012 include charges of $29.1 million of acquired in-process research and development related to our acquisition of assets from S*BIO. See Note 5, Acquisitions, for additional information.

Description_of_Business_and_Su1

Description of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of CTI and its wholly-owned subsidiaries, which include Systems Medicine LLC, or SM, and CTI Life Sciences Limited, or CTILS. CTILS opened a branch in Italy in December 2009. We also retain ownership of our branch, Cell Therapeutics Inc. – Sede Secondaria, or CTI (Europe), however, we ceased operations related to this branch in September 2009. In addition, CTI Commercial LLC, a wholly-owned subsidiary, was included in the consolidated financial statements until dissolution in March 2012.
	As of December 31, 2013, we also had a 61% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements.
	All intercompany transactions and balances are eliminated in consolidation.
Reverse Stock Splits	'
	Reverse Stock-Splits
	On May 15, 2011 and September 2, 2012, we effected one-for-six and one-for-five reverse stock splits, respectively, collectively referred to as the Stock Splits. Unless otherwise noted, all impacted amounts included in the consolidated financial statements and notes thereto have been retroactively adjusted for the Stock Splits. Unless otherwise noted, impacted amounts include shares of common stock authorized and outstanding, share issuances and cancellations, shares underlying preferred stock, convertible notes, warrants and stock options, shares reserved, conversion prices of convertible securities, exercise prices of warrants and options, and loss per share. Additionally, the Stock Splits impacted preferred stock authorized (but not outstanding because there were no shares of preferred stock outstanding as of the time of the applicable reverse stock split).
Capital Requirements	'
	Capital Requirements
	We expect that we will need to raise additional funds to develop our business. We may seek to raise such capital through debt financings, partnerships, collaborations, joint ventures or disposition of assets. Our Board of Directors may issue shares depending on our financial needs and market opportunities, if deemed to be in the best interest of the shareholders. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. Additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we may be required to delay, scale back, or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses and/or refrain from making our contractually required payments when due.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating reserves for sales deductions such as rebates and returns of product sold, allowances for credit losses, excess and obsolete inventory, share-based compensation expense, the allocation of our operating expenses, the allocation of purchase price to acquired assets and liabilities, restructuring charges and our liability for excess facilities, our provision for loss contingencies, the useful lives of fixed assets, the fair value of our financial instruments, our tax provision and related valuation allowance, and determining potential impairment of long-lived assets. Actual results could differ from those estimates.
Certain Risks and Uncertainties	'
	Certain Risks and Uncertainties
	Our results of operations are subject to foreign currency exchange rate fluctuations primarily due to our activity in Europe. We report the results of our operations in U.S. dollars, while the functional currency of our foreign subsidiaries is the euro. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, the reported carrying value of our euro-denominated assets and liabilities that remain in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. We review our foreign currency risk periodically along with hedging options to mitigate such risk.
	Financial instruments which potentially subject us to concentrations of credit risk consist of accounts receivable. The Company has accounts receivable from the sale of PIXUVRI from a small number of distributors and health care providers. Further, the Company does not require collateral on amounts due from its distributors and is therefore subject to credit risk. The Company has not experienced any significant credit losses to date as a result of credit risk concentration and does not consider an allowance for doubtful accounts to be necessary.
	Additionally, see Note 18, Customer and Geographic Concentrations, for further concentration disclosure.
Concentrations	'
	Concentrations
	We source our drug products for commercial operations and clinical trials from a concentrated group of third party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or if we were unable to obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider all highly liquid debt instruments with maturities of three months or less at the time acquired to be cash equivalents. Cash equivalents represent short-term investments consisting of investment-grade corporate and government obligations, carried at cost, which approximates market value.
Accounts Receivable	'
	Accounts Receivable
	Our accounts receivable balance includes trade receivables related to PIXUVRI sales as of December 31, 2013. We estimate an allowance for doubtful accounts based upon the age of outstanding receivables and our historical experience of collections, which includes adjustments for risk of loss for specific customer accounts. We periodically review the estimation process and make changes to our assumptions as necessary. When it is deemed probable that a customer account is uncollectible, the account balance is written off against the existing allowance. We also consider the customers’ country of origin to determine if an allowance is required based on the uncertainty associated with the recent European financial crisis. As of December 31, 2013, our accounts receivable did not include any balance from a customer in a country that has exhibited financial stress that would have had a material impact on our financial results. We did not record an allowance for doubtful accounts as of December 31, 2013.
Value Added Tax Receivable	'
	Value Added Tax Receivable
	Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable is approximately $5.7 million and $8.1 million as of December 31, 2013 and 2012, of which $5.6 million and $5.1 million is included in other assets and $0.1 million and $3.0 million is included in prepaid expenses and other current assets as of December 31, 2013 and 2012, respectively. The collection period of VAT receivable for our European operations ranges from approximately three months to five years. For our Italian VAT receivable, the collection period is approximately three to five years. As of December 31, 2013, the VAT receivable related to operations in Italy is approximately $5.6 million. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.
Inventory	'
	Inventory
	We began capitalizing costs related to the production of PIXUVRI in February 2012 upon receiving a positive opinion for conditional approval by the EMA’s Committee for Medicinal Products for Human Use, or CHMP, at which time the likelihood of receiving conditional approval to market PIXUVRI in the E.U. was deemed probable. Production costs for our other product candidates continue to be charged to research and development expense as incurred prior to regulatory approval or until our estimate for regulatory approval becomes probable. We carry inventory at the lower of cost or market. The cost of finished goods and work in process is determined using the standard-cost method, which approximates actual cost based on a first-in, first-out method. Inventory includes the cost of materials, third-party contract manufacturing and overhead costs, quality control costs and shipping costs from the manufacturers to the final distribution warehouse associated with the production and distribution of PIXUVRI. We regularly review our inventories for impairment and reserves are established when necessary. Estimates of excess inventory consider our projected sales of the product and the remaining shelf lives of product. In the event we identify excess, obsolete or unsaleable inventory, the value is written down to the net realizable value.
Property and Equipment	'
	Property and Equipment
	Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets ranging from three to five years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful life of 10 years or the term of the applicable lease.
Impairment of Long-lived Assets	'
	Impairment of Long-lived Assets
	We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on fair market values.
Leases	'
	Leases
	We analyze leases at the inception of the agreement to classify as either an operating or capital lease. On certain of our lease agreements, the terms include rent holidays, rent escalation clauses and incentives for leasehold improvements. We recognize deferred rent relating to incentives for rent holidays and leasehold improvements and amortize the deferred rent over the term of the leases as a reduction of rent expense. For rent escalation clauses, we recognize rent expense on a straight-line basis equal to the amount of total minimum lease payments over the term of the lease.
Acquisitions	'
	Acquisitions
	We account for acquired businesses using the acquisition method of accounting, which requires that most assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. Any excess of the consideration transferred over the fair value of the net assets acquired is recorded as goodwill, and the fair value of the acquired in-process research and development, or IPR&D, is recorded on the balance sheet. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date.
Fair Value Measurement	'
	Fair Value Measurement
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
	Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, or other inputs that are observable directly or indirectly.
	Level 3 – Unobservable inputs that are supported by little or no market activity, requiring an entity to develop its own assumptions.
	If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Instruments	'
	Financial Instruments
	At December 31, 2013 and 2012, the carrying value of financial instruments such as receivables and payables approximated their fair values based on the short-term maturities of these instruments. The carrying value of our long-term debt approximated its fair value at December 31, 2013 based on borrowing rates for similar loans and maturities.
Contingencies	'
	Contingencies
	We record liabilities associated with loss contingencies to the extent that we conclude the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note 14, Collaboration, Licensing and Milestone Agreements and Note 21, Legal Proceedings, for further information regarding our current gain and loss contingencies.
Revenue Recognition	'
	Revenue Recognition
	We currently have conditional approval to market PIXUVRI in the E.U. Revenue is recognized when there is persuasive evidence of the existence of an agreement, delivery has occurred, prices are fixed or determinable, and collectability is assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria under the provision are met.
	Product Sales
	We sell PIXUVRI directly to health care providers and through a limited number of distributors. We generally record product sales upon receipt of the product by the health care providers and certain distributors at which time title and risk of loss pass. Product sales are recorded net of distributor discounts, estimated government-mandated rebates, trade discounts, and estimated product returns. Reserves are established for these deductions and actual amounts incurred are offset against the applicable reserves. We reflect these reserves as either a reduction in the related account receivable or as an accrued liability depending on the nature of the sales deduction. These estimates are periodically reviewed and adjusted as necessary.
	Government-mandated discounts and rebates
	Our products are subject to certain programs with government entities in the E.U. whereby pricing on products is discounted below distributor list price to participating health care providers. These discounts are provided to participating health care providers either at the time of sale or through a claim by the participating health care providers for a rebate. Due to estimates and assumptions inherent in determining the amount of government discounts and rebates, the actual amount of future claims may be different from our estimates, at which time we would adjust our reserves accordingly.
	Product returns and other deductions
	At the time of sale, we also record estimates for certain sales deductions such as product returns and distributor discounts and incentives. We offer certain distributors a limited right of return or replacement of product that is damaged in certain instances. When we cannot reasonably estimate the amount of future product returns and/or other sales deductions, we do not recognize revenue until the risk of product return and additional sales deductions have been substantially eliminated. To date, there have been no PIXUVRI product returns.
Collaboration agreements	'
	Collaboration agreements
	We evaluate collaboration agreements to determine whether the multiple elements and associated deliverables can be considered separate units of accounting in accordance with ASC 605-25 Revenue Recognition – Multiple-Element Arrangements. If it is determined that the deliverables under the collaboration agreement are a single unit of accounting, all amounts received or due, including any upfront payments, are recognized as revenue over the performance obligation periods of each agreement. Following the completion of the performance obligation period, such amounts will be recognized as revenue when collectability is reasonably assured.
	The assessment of multiple element arrangements requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. In order to account for these agreements, we identify deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.
	Milestone payments under the collaboration agreement are generally aggregated into three categories for reporting purposes: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration, or FDA, or other countries’ regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.
	At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.
Cost of Product Sold	'
	Cost of Product Sold
	Cost of product sold includes third party manufacturing costs, shipping costs, contractual royalties, and other costs of PIXUVRI product sold. Cost of product sold also includes any necessary allowances for excess inventory that may expire and become unsalable. We did not record an allowance for excess inventory as of December 31, 2013.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development costs are expensed as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC 730, Research and Development. Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. In instances where we enter into cost-sharing arrangements, all research and development costs reimbursed by the collaborator are a reduction to research and development expense while research and development costs paid to the collaborator are an addition to research and development expense. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.
Foreign Currency Translation and Transaction Gains and Losses	'
	Foreign Currency Translation and Transaction Gains and Losses
	We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ equity (deficit), except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We and our subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions.
Income Taxes	'
	Income Taxes
	We record a tax provision for the anticipated tax consequences of our reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax base of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. We record a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.
Net Loss per Share	'
	Net Loss per Share
	Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and restricted stock using the treasury stock method.
Recently Adopted Accounting Standards	'
	Recently Adopted Accounting Standards
	In December 2010, the FASB issued additional guidance on when to perform Step 2 of the goodwill impairment test for reporting units with zero or negative carrying amounts. The criteria for evaluating Step 1 of the goodwill impairment test and proceeding to Step 2 were amended for reporting units with zero or negative carrying amounts and require performing Step 2 if qualitative factors indicate that it is more likely than not that a goodwill impairment exists. For public entities, this guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2010. Upon adoption of this guidance on January 1, 2011, we performed Step 2 of the goodwill impairment test. Based on a valuation using the income, market and cost approaches, we determined that all of our $17.1 million in goodwill was impaired. The related charge was recorded as a cumulative-effect adjustment to beginning retained earnings on January 1, 2011. See Note 4, Goodwill, for additional information.
	In June 2011, the FASB issued guidance amending the presentation requirements for comprehensive income. For public entities, this guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 with early adoption permitted. Subsequently, in December 2011, the FASB deferred the effective date of the portion of the June 2011 accounting standards update requiring separate presentation of reclassifications out of accumulated other comprehensive income as discussed below. Upon adoption on January 1, 2012, we had the option to report total comprehensive income, including components of net income and components of other comprehensive income, as a single continuous statement or in two separate, but consecutive statements. We elected to present comprehensive income in two separate, but consecutive statements as part of the accompanying consolidated financial statements.
	In February 2013, the FASB issued guidance requiring presentation of amounts reclassified from each component of accumulated other comprehensive income. In addition, disclosure is required of the effects of significant reclassifications on income statement line items either on the face of the statement where net income is presented or as a separate disclosure in the notes to the financial statements. For public entities, this guidance was effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this guidance did not have a material impact on our consolidated financial statements.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	In March 2013, the Financial Accounting Standards Board, or FASB, issued guidance to clarify when to release cumulative foreign currency translation adjustments when an entity ceases to have a controlling financial interest in a subsidiary or group of assets within a foreign entity. The amendment is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to derecognition events occurring after the effective date. Early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss or tax carryforward exists. FASB concluded that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset except in certain circumstances the unrecognized tax benefit should be presented as a liability and should not be combined with deferred tax assets. The amendment is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with early adoption permitted. We are currently evaluating the impact this amendment may have on our consolidated financial statements.
Reclassifications	'
	Reclassifications
	Certain prior year items have been reclassified to conform to current year presentation.

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Components of Inventories	'
	The components of inventories are composed of the following as of December 31, 2013 and 2012 (in thousands):
		2013		2012
	Finished goods	$	601	$	220
	Work-in-process		4,473		1,406
	Total inventories	$	5,074	$	1,626

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
	Property and equipment is composed of the following as of December 31, 2013 and 2012 (in thousands):
		2013			2012
	Furniture and office equipment	$	10,913		$	11,743
	Leasehold improvements		5,078			5,077
	Lab equipment		143			411
			16,134			17,231
	Less: accumulated depreciation and amortization		(10,656	)		(10,446	)
		$	5,478		$	6,785

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2013
Effects of Cumulative-Effect Application	'
	The following table presents the effects of the cumulative-effect application (in thousands):
		Accumulated			Total Shareholders’
		Deficit			Deficit
	Balance at December 31, 2010	$	(1,576,643	)	$	(5,145	)
	Cumulative effect adjustment		(17,064	)		(17,064	)
	Adjusted Balance at January 1, 2011	$	(1,593,707	)	$	(22,209	)

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Initial Purchase Consideration	'
	The total initial purchase consideration was as follows (in thousands):
	Cash	$	15,000
	Fair value of Series 16 Preferred Stock		11,344
	Transaction costs		2,764
	Total initial purchase consideration	$	29,108

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses	'
	Accrued expenses consisted of the following as of December 31, 2013 and 2012 (in thousands):
		2013		2012
	Clinical and investigator-sponsored trial expenses	$	3,360	$	3,301
	Employee compensation and related expenses		3,035		3,904
	Insurance financing and accrued interest expenses		611		598
	Legal expenses		573		268
	Manufacturing expenses		225		247
	Rebates and royalties		186		—
	Other		1,479		1,891
		$	9,469	$	10,209

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Future Minimum Lease Payments Under Noncancelable Operating Leases	'
	Future minimum lease commitments for non-cancelable operating leases at December 31, 2013 are as follows (in thousands):
		Operating
		Leases
	2014	$	2,534
	2015		2,508
	2016		2,220
	2017		2,280
	2018		2,341
	Thereafter		8,264
	Total minimum lease commitments	$	20,147
Changes in Liability for Excess Facilities	'
	The following table summarizes the changes in the liability for excess facilities during the years ended December 31, 2012 and 2011 (in thousands):
		2005			2010			Total Excess
		Activities			Activities			Facilities
								Liability
	Balance at January 1, 2011	$	550		$	1,410		$	1,960
	Adjustments		40			102			142
	Payments		(375	)		(982	)		(1,357	)
	Balance at December 31, 2011		215			530			745
	Adjustments		(32	)		(62	)		(94	)
	Payments		(183	)		(468	)		(651	)
	Balance at December 31, 2012	$	—		$	—		$	—

Other_Liabilities_Tables

Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Other Liabilities	'
	Other liabilities consisted of the following as of December 31, 2013 and 2012 (in thousands):
		2013			2012
	Deferred rent	$	4,769		$	5,003
	Other long-term obligations		1,281			31
			6,050			5,034
	Less: other current liabilities		(393	)		(393	)
		$	5,657		$	4,641

Convertible_Notes_Tables

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2013
Changes in Principal Balances of Convertible Notes	'
	The following tables summarize the changes in the principal balances of our convertible notes during the year ended December 31, 2011:
		Balance at		Exchanged		Matured			Balance at
		January 1,							December 31,
		2011							2011
	7.5% convertible senior notes	$	10,250	$	—	$	(10,250	)	$	—
	5.75% convertible senior notes		10,913		—		(10,913	)		—
	Total	$	21,163	$	—	$	(21,163	)	$	—

Common_Stock_Tables

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Common Stock Reserved for Issuance	'
	A summary of common stock reserved for issuance is as follows as of December 31, 2013 (in thousands):
	Equity incentive plans	10,094
	Common stock purchase warrants	7,697
	Employee stock purchase plan	38
		17,829

Other_Comprehensive_Loss_Table

Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2013
Total Accumulated Other Comprehensive Loss	'
	Total accumulated other comprehensive loss consisted of the following (in thousands):
		Net Unrealized			Foreign			Accumulated
		Loss on Securities			Currency			Other
		Available-For-Sale			Translation			Comprehensive
					Adjustments			Loss
	December 31, 2012	$	(235	)	$	(8,038	)	$	(8,273	)
	Current period other comprehensive gain (loss)		(187	)		31			(156	)
	December 31, 2013	$	(422	)	$	(8,007	)	$	(8,429	)

Collaboration_Licensing_and_Mi1

Collaboration, Licensing and Milestone Agreements (Tables)	12 Months Ended
	Dec. 31, 2013
License and Contract Revenue Recognized in Statement of Operations Related to Collaboration Agreement	'
	License and contract revenue recognized in the statement of operations related to the Agreement were as follows (in thousands):
		Years ended December 31,
		2013		2012		2011
	License	$	27,275	$	—	$	—
	Development services		89		—		—
	License and contract revenue	$	27,364	$	—	$	—
Deferred Revenue Amounts Related to the Collaboration Agreement	'
	As of December 31, 2013, deferred revenue amounts related to the Agreement consisted of (in thousands):
		December 31,
		2013		2012
	Current portion of deferred revenue	$	1,010	$	—
	Deferred revenue, less current portion		1,626		—
	Total deferred revenue	$	2,636	$	—

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Share-Based Compensation Expense by Types of Awards	'
	For the years ended December 31, 2013, 2012 and 2011, we recognized share-based compensation expense due to the following types of awards (in thousands):
		2013			2012			2011
	Performance rights	$	1,165		$	2,358		$	—
	Restricted stock		5,906			5,180			4,850
	Options		1,995			400			167
	Total share-based compensation expense	$	9,066		$	7,938		$	5,017
Summary of Share-Based Compensation Expense	'
	The following table summarizes share-based compensation expense for the years ended December 31, 2013, 2012 and 2011, which was allocated as follows (in thousands):
		2013			2012			2011
	Research and development	$	2,178		$	1,730		$	1,126
	Selling, general and administrative		6,888			6,208			3,891
	Total share-based compensation expense	$	9,066		$	7,938		$	5,017
Schedule of Black Scholes Stock Option Pricing Model Weighted Average Assumptions	'
	Fair value for employee stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:
		Year Ended December 31,
		2013			2012			2011
	Risk-free interest rate		1.4	%		0.8	%		0.9	%
	Expected dividend yield		None			None			None
	Expected life (in years)		5.3			4.7			4.5
	Volatility		102	%		88	%		97	%
Stock Option Activity for All Stock Plans	'
	The following table summarizes stock option activity for all of our stock option plans:
		Options			Weighted			Weighted			Aggregate
					Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price			Contractual			(Thousands)
								Term (Years)
	Outstanding at January 1, 2011 (17,000 exercisable)		34,000		$	744.74
	Granted		126,000		$	5.48
	Exercised		—		$	—
	Forfeited		(2,000	)	$	9.91
	Cancelled and expired		(2,000	)	$	6,740.99
	Outstanding at December 31, 2011 (59,000 exercisable)		156,000		$	90.07
	Granted		179,000		$	4.92
	Exercised		—		$	—
	Forfeited		(23,000	)	$	5.93
	Cancelled and expired		(5,000	)	$	886.13
	Outstanding at December 31, 2012 (105,000 exercisable)		307,000		$	33.72
	Granted		4,352,000		$	1.71
	Exercised		—		$	—
	Forfeited		(112,000	)	$	2.4
	Cancelled and expired		(28,000	)	$	133.72
	Outstanding at December 31, 2013		4,519,000		$	3.04			9.53		$	889
	Vested or expected to vest at December 31, 2013		4,241,404		$	3.12			9.53		$	842
	Exercisable at December 31, 2013		1,560,000		$	5.39			9.54		$	358
Summary of Status of Nonvested Restricted Stock Awards	'
	A summary of the status of nonvested restricted stock awards as of December 31, 2013 and changes during the period then ended, is presented below:
		Nonvested Shares			Weighted Average
					Grant-Date Fair Value
					Per Share
	Nonvested at December 31, 2012		3,322,000		$	5.26
	Issued		6,375,000		$	1.21
	Vested		(3,841,000	)	$	1.83
	Forfeited		(1,168,000	)	$	3.7
	Nonvested at December 31, 2013		4,688,000		$	2.95

Customer_and_Geographic_Concen1

Customer and Geographic Concentrations (Tables)	12 Months Ended
	Dec. 31, 2013
Product Sales from Major Customers	'
	All sales of PIXUVRI during 2013 were in Europe. Product sales from PIXUVRI’s major customers as a percentage of total product sales were as follows:
		Year Ended
		December 31,
		2013
	Customer A		67	%
	Customer B		4	%
	Customer C		3	%
Long-Lived Assets Based on Geographical Locations	'
	The following table depicts long-lived assets based on the following geographic locations (in thousands):
		Year Ended December 31,
		2013			2012
	United States	$	5,336		$	6,570
	Europe		142			215
		$	5,478		$	6,785

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Calcualation of Basic and Diluted Net Loss Per Share Using Weighted Average Number of Shares Outstanding	'
	Basic and diluted net loss per share is calculated using the weighted average number of shares outstanding as follows (in thousands, except per share amounts):
		Year Ended December 31,
		2013			2012			2011
	Net loss attributable to common shareholders	$	(49,643	)	$	(115,275	)	$	(121,078	)
	Basic and diluted:
	Weighted average shares outstanding		119,042			62,021			35,790
	Less weighted average restricted shares outstanding		(4,847	)		(3,896	)		(1,496	)
	Shares used in calculation of basic and diluted net loss per common share		114,195			58,125			34,294
	Net loss per common share: Basic and diluted	$	(0.43	)	$	(1.98	)	$	(3.53	)

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Reconciliation Between Effective Tax Rate and Income Tax Rate	'
	The reconciliation between our effective tax rate and the income tax rate as of December 31, 2013, 2012 and 2011 is as follows:
		2013			2012			2011
	Federal income tax rate		(34	%)		(34	%)		(34	%)
	Research and development tax credits		(3	)		—			(2	)
	I.R.C. Section 382 limited research and development tax credits		—			1			—
	Non-deductible debt/equity costs		—			—			1
	Non-deductible executive compensation		1			1			1
	I.R.C. Section 382 limited net operating losses		3			134			21
	Valuation allowance		27			(111	)		6
	Expired tax attribute carryforwards		—			7			7
	Foreign tax rate differential		6			1			—
	Other		—			1			—
	Net effective tax rate		—	%		—	%		—	%
Significant Components of Deferred Tax Assets and Liabilities	'
	Significant components of our deferred tax assets and liabilities as of December 31, 2013 and 2012 were as follows (in thousands):
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	49,777		$	34,655
	Capitalized research and development		31,046			36,303
	Research and development tax credit carryforwards		1,486			223
	Stock based compensation		12,097			10,813
	Intangible assets		10,518			11,336
	Depreciation and amortization		96			8
	Other deferred tax assets		3,062			3,621
	Total deferred tax assets		108,082			96,959
	Less valuation allowance		(107,271	)		(95,949	)
			811			1,010
	Deferred tax liabilities:
	GAAP adjustments on Novuspharma merger		(208	)		(208	)
	Deductions for tax in excess of financial statements		(603	)		(802	)
	Total deferred tax liabilities		(811	)		(1,010	)
	Net deferred tax assets	$	—		$	—

Unaudited_Quarterly_Data_Table

Unaudited Quarterly Data (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Quarterly Financial Information	'
	The following table presents summarized unaudited quarterly financial data (in thousands, except per share data):
			First			Second			Third			Fourth
			Quarter			Quarter			Quarter			Quarter
	2013
	Total revenues (1)		$	1,126		$	306		$	362		$	32,884
	Product sales, net			1,126			306			362			520
	Gross profit			1,071			270			349			487
	Operating costs and expenses			(19,553	)		(18,158	)		(15,942	)		(22,551	)
	Net income (loss) attributable to CTI			(19,384	)		(18,011	)		(15,544	)		10,196
	Net income (loss) attributable to CTI common shareholders			(19,384	)		(18,011	)		(22,444	)		10,196
	Net income (loss) per common share—basic			(0.18	)		(0.17	)		(0.20	)		0.08
	Net income (loss) per common share—diluted			(0.18	)		(0.17	)		(0.20	)		0.08
	2012
	Total revenues		$	—		$	—		$	—		$	—
	Product sales, net			—			—			—			—
	Gross profit			—			—			—			—
	Operating costs and expenses (2)			(18,098	)		(49,400	)		(15,149	)		(18,850	)
	Net loss attributable to CTI			(17,446	)		(50,138	)		(15,189	)		(18,601	)
	Net loss attributable to CTI common shareholders			(17,446	)		(58,596	)		(20,203	)		(19,030	)
	Net loss per common share—basic			(0.43	)		(1.38	)		(0.38	)		(0.20	)
	Net loss per common share—diluted			(0.43	)		(1.38	)		(0.38	)		(0.20	)
	-1	Total revenues for the fourth quarter of 2013 include $27.4 million of license and contract revenue recognized in connection with the collaboration agreement with Baxter in November 2013 and $5.0 million of license and contract revenue from Teva in November 2013 upon the achievement of a worldwide net sales milestone of TRISENOX. See Note 14, Collaboration, Licensing and Milestone Agreements, for additional information.
	-2	Operating costs and expenses for the second quarter of 2012 include charges of $29.1 million of acquired in-process research and development related to our acquisition of assets from S*BIO. See Note 5, Acquisitions, for additional information.

Description_of_Business_and_Su2

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 02, 2012	15-May-11	Dec. 31, 2013	Dec. 31, 2012
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
Reverse stock split ratios	0.2	0.1667	'	'
Preferred stock outstanding	0	0	'	'
VAT receivable	'	'	$5.70	$8.10
Goodwill impaired	'	'	17.1	'
ITALY	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
VAT receivable	'	'	5.6	'
Minimum | Assets Other Than Leasehold Improvements	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
Property, plant and equipment useful life	'	'	'3 years	'
Minimum | Europe	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
VAT receivable, collection period	'	'	'3 months	'
Minimum | ITALY	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
VAT receivable, collection period	'	'	'3 years	'
Maximum | Assets Other Than Leasehold Improvements	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
Property, plant and equipment useful life	'	'	'5 years	'
Maximum | Leasehold Improvements	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
Property, plant and equipment useful life	'	'	'10 years	'
Maximum | Europe	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
VAT receivable, collection period	'	'	'5 years	'
Maximum | ITALY	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
VAT receivable, collection period	'	'	'5 years	'
Other Assets	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
VAT receivable	'	'	5.6	5.1
Prepaid Expenses and Other Current Assets	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
VAT receivable	'	'	$0.10	$3
Aequus Biopharma, Inc	'	'	'	'
Description Of Business And Significant Accounting Policies [Line Items]	'	'	'	'
Interest in majority-owned subsidiary	'	'	61.00%	'

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Finished goods	$601	$220
Work-in-process	4,473	1,406
Total inventories	$5,074	$1,626

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Furniture and office equipment	$10,913	$11,743
Leasehold improvements	5,078	5,077
Lab equipment	143	411
Property and Equipment, Gross, Total	16,134	17,231
Less: accumulated depreciation and amortization	-10,656	-10,446
Property and equipment, net	$5,478	$6,785

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation expense	$1,570	$2,346	$2,411

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Jan. 31, 2011
Goodwill [Line Items]	'	'
Fair value of goodwill	'	$0
Goodwill impairment charges	$17.10	'

Effects_of_CumulativeEffect_Ap

Effects of Cumulative-Effect Application (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2011	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Revisions [Line Items]	'	'	'	'	'
Beginning balance	($5,145)	$28,009	$42,758	$32,944	($5,145)
Cumulative effect adjustment	-17,064	-17,064	'	'	'
Adjusted Balance at January 1, 2011	-22,209	'	'	'	'
Retained Earnings	'	'	'	'	'
Revisions [Line Items]	'	'	'	'	'
Beginning balance	-1,576,643	-1,714,785	-1,879,703	-1,830,060	-1,576,643
Cumulative effect adjustment	-17,064	-17,064	'	'	'
Adjusted Balance at January 1, 2011	($1,593,707)	'	'	'	'

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	12 Months Ended	3 Months Ended		1 Months Ended		12 Months Ended		1 Months Ended
	Dec. 31, 2012	Jun. 30, 2012	31-May-12	Jun. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	31-May-12	31-May-12	Dec. 31, 2013
		Assets from S*BIO Pte Ltd.	Assets from S*BIO Pte Ltd.	Assets from S*BIO Pte Ltd.	S*BIO Pte Ltd	S*BIO Pte Ltd	S*BIO Pte Ltd	S*BIO Pte Ltd	S*BIO Pte Ltd
				Series 16 Preferred Stock		Assets from S*BIO Pte Ltd.	Assets from S*BIO Pte Ltd.	Assets from S*BIO Pte Ltd.	Assets from S*BIO Pte Ltd.
								Series 16 Preferred Stock	Maximum
Research and Development Assets Acquired Other than Through Business Combination [Line Items]	'	'	'	'	'	'	'	'	'
Asset acquisition, cash	'	'	$15,000,000	'	'	'	$15,000,000	'	'
Asset acquisition, shares	'	'	'	'	'	'	'	15,000	'
Preferred stock stated value	'	'	'	'	'	'	'	$1,000	'
Issuance of common stock upon conversion of convertible securities	'	'	'	2,500,000	'	'	'	'	'
Preferred stock, conversion price	'	'	'	$5.95	'	'	'	'	'
Preferred stock conversion blocker provision	'	'	'	19.99%	'	'	'	'	'
Asset acquisition purchase price allocation in process research and development	29,108,000	29,108,000	'	'	'	29,108,000	'	'	'
Contingent milestone payment	'	'	'	'	'	'	'	'	$132,500,000
Milestone payments through issuance of stock	'	'	'	'	50.00%	'	'	'	'

Initial_Purchase_Consideration

Initial Purchase Consideration (Detail) (Assets from S*BIO Pte Ltd., USD $)	31-May-12
In Thousands, unless otherwise specified
Assets from S*BIO Pte Ltd.	'
Asset Acquisition [Line Items]	'
Cash	$15,000
Fair value of Series 16 Preferred Stock	11,344
Transaction costs	2,764
Total initial purchase consideration	$29,108

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Clinical and investigator-sponsored trial expenses	$3,360	$3,301
Employee compensation and related expenses	3,035	3,904
Insurance financing and accrued interest expenses	611	598
Legal expenses	573	268
Manufacturing expenses	225	247
Rebates and royalties	186	'
Other	1,479	1,891
Accrued expenses	$9,469	$10,209

Leases_Additional_Information_

Leases - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2012
	sqft				2005 Activities	Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets
Operating Lease Agreements [Line Items]	'	'	'	'	'	'	'
Rent expense, net sublease income	'	$2	$2.70	$1.50	'	'	'
Lease agreement area	66,000	'	'	'	'	'	'
Lease term	'120 months	'	'	'	'	'	'
Number of option to extend the term	2	'	'	'	'	'	'
Extend option term	'5 years	'	'	'	'	'	'
Initial annual rent payments per square foot	27	'	'	'	'	'	'
Percentage of rent Increase over the prior years	3.00%	'	'	'	'	'	'
Allowance Tenant Improvements	3.3	'	'	'	'	0	1.5
Additional liability for excess facilities charge	'	'	'	'	$1.50	'	'

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Operating Leases Future Minimum Payments	'
2014	$2,534
2015	2,508
2016	2,220
2017	2,280
2018	2,341
Thereafter	8,264
Total minimum lease commitments	$20,147

Changes_in_Liability_for_Exces

Changes in Liability for Excess Facilities (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'
Beginning balance	$745	$1,960
Adjustments	-94	142
Payments	-651	-1,357
Ending balance	'	745
2005 Activities	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Beginning balance	215	550
Adjustments	-32	40
Payments	-183	-375
Ending balance	'	215
2010 Activities	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Beginning balance	530	1,410
Adjustments	-62	102
Payments	-468	-982
Ending balance	'	$530

Other_Liabilities_Detail

Other Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule Of Other Liabilities Noncurrent [Line Items]	'	'
Deferred rent	$4,769	$5,003
Other long-term obligations	1,281	31
Other Accrued Liabilities, Total	6,050	5,034
Less: other current liabilities	-393	-393
Long-term obligations, less current portion	$5,657	$4,641

Other_Liabilities_Additional_I

Other Liabilities - Additional Information (Detail) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Schedule Of Other Liabilities Noncurrent [Line Items]	'
Fees payable	$1.30

Changes_in_Principal_Balances_

Changes in Principal Balances of Convertible Notes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011
Debt Instrument [Line Items]	'
Beginning Balance	$21,163
Exchanged	'
Matured	-21,163
Ending Balance	'
7.5% convertible senior notes	'
Debt Instrument [Line Items]	'
Beginning Balance	10,250
Exchanged	'
Matured	-10,250
Ending Balance	'
5.75% convertible senior notes	'
Debt Instrument [Line Items]	'
Beginning Balance	10,913
Exchanged	'
Matured	-10,913
Ending Balance	'

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (USD $)	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2013	Jan. 31, 2014
		Senior Secured Term Loan	Senior Secured Term Loan	Senior Secured Term Loan	Senior Secured Term Loan	Senior Secured Term Loan
		Installment		Warrants	Warrants	Warrants
						Subsequent Event
Debt Instrument [Line Items]	'	'	'	'	'	'
Debt instrument maximum borrowing capacity	'	$15,000,000	'	'	'	'
Debt instrument issued	'	10,000,000	5,000,000	'	'	'
Interest rate terms	'	'The interest rate on the term loan floats at a rate per annum equal to 12.25% plus the amount by which the prime rate exceeds 3.25%.	'	'	'	'
Debt instrument term	'	'42 months	'	'	'	'
Interest-only period	'	'12 months	'	'	'	'
Debt instrument number of monthly installments	'	30	'	'	'	'
Facility charge	'	150,000	'	'	'	'
Fee amount on term loan	'	1,300,000	'	'	'	'
Debt instrument discount	'	2,100,000	'	'	'	'
Debt instrument issuance cost	'	300,000	'	'	'	'
Debt instrument unamortized discount	'	'	1,700,000	'	'	'
Debt instrument unamortized issuance cost	'	'	300,000	'	'	'
Warrant exercisable period	'	'	'	'5 years	'	'
Number of warrant issued	'	'	'	700,000	'	'
Warrant exercise price	'	'	'	1.1045	'	'
Fair value of warrant	$991,000	'	'	$1,000,000	$500,000	'
Warrants exercised into shares of common stock	'	'	'	'	'	500,000

Preferred_Stock_Additional_Inf

Preferred Stock - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 31, 2011

Feb. 28, 2011

31-May-11

Dec. 31, 2011

31-May-12

Jul. 31, 2012

Oct. 31, 2012

Jul. 31, 2011

Mar. 31, 2011

Jan. 31, 2011

Dec. 31, 2011

Jan. 31, 2011

Jan. 31, 2011

Jan. 31, 2011

Mar. 31, 2011

Feb. 28, 2011

Dec. 31, 2011

Feb. 28, 2011

Feb. 28, 2011

Feb. 28, 2011

31-May-11

Dec. 31, 2011

31-May-11

Dec. 31, 2013

31-May-11

Dec. 31, 2013

Jul. 31, 2011

Dec. 31, 2011

Jul. 31, 2011

Dec. 31, 2013

Jul. 31, 2011

Dec. 31, 2013

Jul. 31, 2011

Dec. 31, 2013

Jan. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

31-May-12

Dec. 31, 2012

Nov. 30, 2012

Sep. 30, 2012

31-May-12

Jul. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2012

Jul. 31, 2012

Oct. 31, 2012

Dec. 31, 2012

Oct. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Series 8 Financing Deal

Series 10 Financing Deal

Series 12 Financing Deal

Series 14 Financing Deal

Series 15-1 Financing Deal

Series 15-2 Financing Deal

Series 17 Financing Deal

Series 13 Financing Deal

Series 8 preferred Stock

Series 8 preferred Stock

Series 8 preferred Stock

Series 8 preferred Stock

Series 9 preferred Stock

Series 9 preferred Stock

Series 10 preferred Stock

Series 10 preferred Stock

Series 10 preferred Stock

Series 10 preferred Stock

Series 11 preferred Stock

Series 11 preferred Stock

Series 12 preferred Stock

Series 12 preferred Stock

Series 12 preferred Stock

Series 12 preferred Stock

Series 12 preferred Stock

Series 12 preferred Stock

Series 13 preferred Stock

Series 13 preferred Stock

Series 13 preferred Stock

Series 13 preferred Stock

Series 13 preferred Stock

Series 13 preferred Stock

Series 13 preferred Stock

Series 13 preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 14 Preferred Stock

Series 15-1 Preferred Stock

Series 15-1 Preferred Stock

Series 15-1 Preferred Stock

Series 15-1 Preferred Stock

Series 15-1 Preferred Stock

Series 15-2 Preferred Stock

Series 15-2 Preferred Stock

Series 15-2 Preferred Stock

Series 15-2 Preferred Stock

Series 15-2 Preferred Stock

Series 17 Preferred Stock

Series 17 Preferred Stock

Series 17 Preferred Stock

Series 18 Preferred Stock

Series 18 Preferred Stock

Warrants

Additional Investment Right

Warrants

Additional Investment Right

Warrants

Warrants

Placement Agent

Placement Agent

Warrants

Warrants

Placement Agent

Placement Agent

Financial Advisory

Financial Advisory

Warrants

Warrants

Placement Agent

Placement Agent

Financial Advisory

Financial Advisory

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Underwriters Commissions and Discounts

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

24,957

'

'

'

'

15,972

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

20,000

'

'

'

'

15,000

'

'

'

'

60,000

'

'

15,000

'

Warrants or rights issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

25,000

'

'

'

900,000

'

24,957

'

'

600,000

'

30,423

'

'

'

1,800,000

'

70,588

'

35,294

'

'

'

'

1,400,000

'

69,566

'

34,783

'

'

'

'

'

2,700,000

'

'

'

'

3,400,000

'

'

'

'

'

Aggregate offering price

'

'

'

$25,000,000

$25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceed from issuance of preferred stock and warrants

'

'

'

23,700,000

23,700,000

16,000,000

20,000,000

20,000,000

15,000,000

'

30,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds allocated to the security instrument

'

'

'

'

'

'

'

'

'

'

'

'

18,500,000

'

1,300,000

'

3,900,000

'

18,500,000

'

1,300,000

'

3,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitment Fee

'

'

'

5.00%

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance costs

'

'

'

500,000

300,000

1,200,000

1,600,000

1,300,000

800,000

5,500,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,900,000

100,000

'

Annual dividend rate

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11.634

'

'

'

'

'

10.11

'

'

'

'

12

'

13.125

'

'

'

10.75

'

12.25

'

12.25

'

'

'

'

7.25

'

8.625

'

8.625

'

'

'

'

'

5.46

'

'

3.0672

'

'

'

'

'

'

'

Warrant, expiration date, YM

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2013-01

'

'2011-02

'

'

'

'2013-02

'

'2011-03

'

'

'2016-05

'

'2016-05

'

'

'

'2016-07

'

'2016-07

'

'2016-07

'

'

'

'

'2016-12

'

'2016-12

'

'2016-12

'

'

'

'

'

'2017-05

'

'

'2017-07

'

'

'

'

'

'

'

Number of warrants or rights exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

25,000

'

'

'

900,000

'

24,957

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant or right exercise value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,800,000

'

25,000,000

'

'

'

8,700,000

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock stated value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

$1,000

'

'

'

'

$1,000

'

'

$1,000

'

Number of preferred stock converted to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

24,957

'

15,972

'

'

'

'

'

30,000

'

'

'

'

'

'

'

10,000

10,000

'

'

'

'

'

'

'

20,000

'

'

'

'

15,000

'

'

'

'

'

60,000

'

15,000

'

Issuance of common stock upon conversion of convertible securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

'

2,500,000

'

1,500,000

'

'

'

'

'

3,500,000

'

'

'

'

'

'

'

1,700,000

1,700,000

'

'

'

'

'

'

'

4,000,000

'

'

'

'

5,000,000

'

'

'

'

'

42,900,000

'

15,000,000

'

Conversion Price per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$11.63

'

'

'

'

'

$10.11

'

$10.50

'

'

'

'

'

$8.50

'

'

'

'

'

'

'

$5.75

$5.75

'

'

'

'

'

'

'

$5

'

'

'

'

$2.97

'

'

'

'

'

$1.40

'

$1

'

Redemption of preferred stock

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

24,957

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal balance of recourse Notes, per note

'

'

'

'

'

'

'

'

'

'

'

1,350

'

'

'

'

'

1,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal balance of recourse Notes

'

'

'

'

'

'

'

'

'

'

'

33,900,000

'

'

'

'

'

33,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Dividends

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Interest Recourse Notes

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

41,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividends on preferred stock

6,900,000

13,901,000

58,718,000

'

'

'

'

'

'

'

'

'

'

15,500,000

'

'

'

'

'

15,400,000

'

'

'

'

5,500,000

'

'

'

'

'

13,000,000

'

'

'

'

'

'

'

'

8,900,000

'

'

'

'

'

'

'

8,500,000

'

'

'

'

5,000,000

'

'

'

'

400,000

'

'

6,900,000

Preferred stock carrying amount at redemption date

'

'

'

'

'

'

'

'

'

'

'

18,400,000

'

'

'

'

'

18,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated fair value of warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,100,000

'

200,000

'

'

'

8,400,000

'

300,000

'

200,000

'

'

'

'

4,900,000

'

200,000

'

100,000

'

'

'

'

'

10,300,000

'

'

7,200,000

'

'

'

'

'

'

'

Common stock warrant outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

30,423

'

'

'

1,800,000

'

70,588

'

35,294

'

'

'

'

1,400,000

'

69,566

'

34,783

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant, exercise period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months 1 day

'

'6 months 1 day

'

'6 months 1 day

'

'

'

'

'6 months 1 day

'

'6 months 1 day

'

'6 months 1 day

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, description of liquidation preference

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Each share of our Series 15-1 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series 15-1 Preferred Stock, plus any accrued and unpaid dividends before the holders of our common stock or any other junior securities receive any payments upon such liquidation.

'

'

'

'

'Each share of our Series 15-2 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series 15-2 Preferred Stock, plus any accrued and unpaid dividends before the holders of our common stock or any other junior securities receive any payments upon such liquidation.

'

'

'

'

'Each share of Series 17 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the stated value of $1,000 per share plus any accrued and unpaid dividends before the holders of our common stock or any other junior securities receive any payments upon such liquidation.

'

'

'

'

Number of warrants exchanged

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

1,300,000

'

'

'

'

3,400,000

'

'

'

'

'

'

Warrant exchange value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,400,000

5,000,000

'

'

'

'

7,400,000

'

'

'

'

'

'

Number of shares issued upon exchange of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,100,000

2,800,000

'

'

'

'

2,900,000

'

'

'

'

'

'

Proceeds from issuance of preferred stock

'

'

'

'

'

'

'

'

'

60,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceed from issuance of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15,000,000

'

Summary_of_Common_Stock_Reserv

Summary of Common Stock Reserved for Issuance (Detail)	Dec. 31, 2013
Components of Common Stock Reserved [Line Items]	'
Common stock reserved for issuance	17,829,000
Equity Incentive Plans	'
Components of Common Stock Reserved [Line Items]	'
Common stock reserved for issuance	10,094,000
Warrants	'
Components of Common Stock Reserved [Line Items]	'
Common stock reserved for issuance	7,697,000
Employee Stock Purchase Plan	'
Components of Common Stock Reserved [Line Items]	'
Common stock reserved for issuance	38,000

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Series 1 Preferred Stock | Warrants	'
Class of Warrant or Right [Line Items]	'
Warrants outstanding	100,000
Warrant, exercise price	12.3
Warrant Expiration Month Year	'2014-10
Series 1 Preferred Stock | Placement Agent	'
Class of Warrant or Right [Line Items]	'
Warrants outstanding	5,000
Warrant, exercise price	13.5
Warrant Expiration Month Year	'2014-10
Common Stock Offering Warrants | Warrants	'
Class of Warrant or Right [Line Items]	'
Warrants outstanding	200,000
Warrant, exercise price	42
Warrant Expiration Month Year	'2014-05
Common Stock Offering Warrants | Placement Agent	'
Class of Warrant or Right [Line Items]	'
Warrants outstanding	10,667
Warrant, exercise price	46.875
Warrant Expiration Month Year	'2014-11
Common Stock Offering Warrants | Underwriter	'
Class of Warrant or Right [Line Items]	'
Warrants outstanding	19,556
Warrant, exercise price	51
Warrant Expiration Month Year	'2014-04

Total_Accumulated_Other_Compre

Total Accumulated Other Comprehensive Loss (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning balance	($8,273)	'	'
Current period other comprehensive gain (loss)	-156	-238	-66
Ending balance	-8,429	-8,273	'
Net Unrealized Gain (Loss) on Securities Available-for-sale	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning balance	-235	'	'
Current period other comprehensive gain (loss)	-187	'	'
Ending balance	-422	'	'
Foreign Currency Translation Adjustments	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning balance	-8,038	'	'
Current period other comprehensive gain (loss)	31	'	'
Ending balance	($8,007)	'	'

Collaboration_Licensing_and_Mi2

Collaboration, Licensing and Milestone Agreements - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Nov. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 30, 2013

Dec. 31, 2013

Nov. 30, 2013

Dec. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jan. 31, 2014

Jan. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Jan. 31, 2014

Series 19 Preferred Stock

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Baxter

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

Chroma Therapeutics, Ltd

PG-TXL

Novartis

Novartis

Nerviano Medical Sciences

Cephalon, Inc

Cephalon, Inc

Gynecologic Oncology Group

Gynecologic Oncology Group

Gynecologic Oncology Group

Maximum

United States Territory

CTIC

License and Development Services Agreement

License

License

Development Services

Development Services

Up-front Payment Arrangement

Up-front Payment Arrangement

Development Milestone Payments

Sales Events Milestone

Accrued Expense

Accrued Expense

Licensing Agreements

Standstill Agreement

CTIC

Chroma

License Agreement Extended Period

Maximum

Subsequent Event

Subsequent Event

Maximum

TRISENOX

Maximum

Milestones

Accounts Payable

Subsequent Event

Series 19 Preferred Stock

Maximum

Maximum

PIXUVRI

Maximum

License Revenue

TRISENOX

Patient

PIXUVRI

Terms and Conditions of Significant Agreements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

'

'

$2,636,000

'

'

'

'

$30,000,000

'

$27,300,000

$2,636,000

$2,700,000

$60,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of preferred stock

29,840,000

'

'

'

'

'

'

'

'

'

'

'

'

29,840,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent milestone payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

112,000,000

190,000,000

5,000,000

'

'

'

'

'

'

'

'

'

14,400,000

'

'

80,000,000

'

'

1,200,000

'

'

Percentage of net sales reduction description

'

'

'Outside the U.S., the Company is also eligible to receive tiered high single digit to mid-teen percentage royalties based on net sales for myelofibrosis, and higher double-digit royalties for other indications, subject to reduction by up to 50% if (i) Baxter is required to obtain additional third party licenses, on which it is obligated to pay royalties, to fulfill its obligations under the Agreement, and (ii) in any jurisdiction where there is no longer either regulatory exclusivity or patent protection.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum amount allowed for the development costs

'

'

'

96,000,000

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Development cost percentage

'

'

'

'

75.00%

100.00%

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75.00%

25.00%

'

'

'

'

'

'

'

'

'

'

Agreement terms

'

'

'Under the Agreement, the Company is responsible for all development costs incurred prior to January 1, 2014 as well as approximately up to $96.0 million on or after January 1, 2014 for U.S. and E.U. development costs, subject to potential upward or downward adjustment in certain circumstances. All development costs exceeding such threshold will generally be shared as follows: (i) costs generally applicable worldwide will be shared 75% to Baxter and 25% to the Company, (ii) costs applicable to territories exclusive to Baxter will be 100% borne by Baxter and (iii) costs applicable exclusively to co-promotion in the U.S. will be shared equally between the parties, subject to certain exceptions.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Manufacturing of licensed products, contract term

'

'

'

'180 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License revenue

'

'

'

'

'

'

'

'

27,275,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

Revenue related to development services

'

'

'

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue recognized

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, no par value

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of convertible preferred stock

'

30,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance costs

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, initial stated value

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of Preferred Stock converted into common stock

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon conversion of convertible securities

'

'

15,673,981

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion Price per Share

'

'

$1.91

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential future milestone payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,600,000

'

'

'

'

'

'

Percentage of royalty payable to net sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

Royalty payment description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Novartis is also eligible to receive tiered low single-digit percentage royalty payments for the first several hundred million in annual net sales, and ten percent royalty payments thereafter based on annual net sales of each Compound, subject to reduction in the event generic drugs are introduced and sold by a third party, causing the sale of PIXUVRI or Opaxio to fall by a percentage in the high double-digits.

'

'

'

'

'

'

'

Upfront fees upon execution of agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

2,800,000

7,000,000

100,000

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Development and sales based milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

209,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement termination period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'120 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License Agreement cure period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'90 days

'

'

'

'

'

'

'

'

'180 days

'

'

'

'

'

'

'

'

'

Agreement entry date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25-Sep-12

'

'

'

'

'

'

'

'

'

'

'

'

Agreement extended expiry date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25-Jun-13

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

Accrued expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

Number of patients enrolled

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,150

Milestones and fees, receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000,000

'

'

'

License_and_Contract_Revenue_R

License and Contract Revenue Recognized in Statement of Operations Related to Collaboration Agreement (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Revenue Recognition [Line Items]	'
License and contract revenue	$32,364
Baxter	'
Revenue Recognition [Line Items]	'
License and contract revenue	27,364
Baxter | License	'
Revenue Recognition [Line Items]	'
License	27,275
Baxter | Development Services	'
Revenue Recognition [Line Items]	'
Development services	$89

Deferred_Revenue_Amounts_Relat

Deferred Revenue Amounts Related to the Collaboration Agreement (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Revenue [Line Items]	'
Current portion of deferred revenue	$1,010
Deferred revenue, less current portion	1,626
Baxter	'
Deferred Revenue [Line Items]	'
Current portion of deferred revenue	1,010
Deferred revenue, less current portion	1,626
Total deferred revenue	$2,636

ShareBased_Compensation_Expens

Share-Based Compensation Expense by Types of Awards (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	$9,066	$7,938	$5,017
Performance Rights	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	1,165	2,358	'
Restricted stock	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	5,906	5,180	4,850
Stock Options	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	$1,995	$400	$167

Summary_of_ShareBased_Compensa

Summary of Share-Based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	$9,066	$7,938	$5,017
Research and development	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	2,178	1,730	1,126
Selling, general and administrative	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	$6,888	$6,208	$3,891

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2014

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

2007 Equity Incentive Plan

ESPP

ESPP

ESPP

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Long Term Performance Awards

Long Term Performance Awards

Long Term Performance Awards

Long Term Performance Awards

Long Term Performance Awards

Long Term Performance Awards

Long Term Performance Awards

Restricted stock

Restricted stock

Restricted stock

Restricted stock

Restricted stock

Restricted stock

Restricted stock

Restricted stock

Nonvested Nonemployee Shares

Nonvested Nonemployee Shares

Subsequent Event

PIXUVRI MAA Performance Goal

Market-based Performance Goal

Market-based Performance Goal

Market-based Performance Goal

Vested shares

Vested shares

Vested shares

Nonvested Shares

Nonvested Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

$9,066,000

$7,938,000

$5,017,000

'

'

'

'

$1,995,000

$400,000

$167,000

'

'

'

'

'

'

$1,100,000

$1,200,000

$1,300,000

'

$5,906,000

$5,180,000

$4,850,000

'

'

'

'

'

Effect on basic and diluted net loss per common share

'-0.08

'-0.14

'-0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchased shares of our common stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

23,000

44,000

'

'

Repurchased shares of our common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

100,000

400,000

'

'

Share-based Compensation, unrecognized compensation cost

8,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, recognition period

'1 year 1 month 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options expiration period

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized for issuance

'

'

'

21,500,000

50,833

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for future grants

'

'

'

5,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price of options exercisable

'

'

'

'

'

'

'

$5.39

$89.08

$228.95

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average fair value of options granted

'

'

'

'

'

'

'

$1.32

$3.28

$3.93

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued in Period

'

'

'

'

'

'

'

6,400,000

4,300,000

1,700,000

'

'

'

'

'

'

'

'

'

'

6,375,000

'

'

'

'

'

'

'

Weighted average fair value of restricted shares issued

'

'

'

'

'

'

'

$1.21

$4.77

$6.23

'

'

'

'

'

'

'

'

'

'

$1.21

'

'

'

'

'

'

'

Share-based compensation arrangement by share payment award, non-option equity instruments forfeiture

'

'

'

'

'

'

'

1,200,000

900,000

1,200,000

'

'

'

'

'

'

'

'

'

'

1,168,000

'

'

'

'

'

'

'

Total fair value of vested restricted stock awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,100,000

3,400,000

3,500,000

'

'

Total award percentages of shares outstanding for senior management

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total award percentages of shares outstanding for director participants

'

'

'

'

'

'

'

'

'

'

'

'

'

2.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Shares Vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

3,841,000

'

'

'

'

'

'

'

Share-based compensation arrangement total award forfeited percentages for Officers

'

'

'

'

'

'

'

'

'

'

'

'

'

0.90%

2.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

Total grant-date fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,800,000

'

'

'

'

'

'

'

'

'

'

Grant-date fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

'

'

'

Extended expiration date of Long-Term Performance Award

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-16

'

'

'

'

'

'

'

'

'

'

'

'

Options to acquire shares of common stock, outstanding

'

'

'

'

'

'

'

4,519,000

307,000

156,000

34,000

157,000

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested nonemployee restricted stock awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

163,000

2,000

Compensation expense related to nonemployee stock options and restricted stock awards

$310,000

$1,000

$58,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ESPP Information

'

'

'

'

'Under our 2007 Employee Stock Purchase Plan, as amended and restated in August 2009, or the Purchase Plan, eligible employees may purchase a limited number of shares of our common stock at 85% of the lower of the subscription date fair market value and the purchase date fair market value.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued in Period

'

'

'

'

3,000

3,000

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock reserved for future issuance

17,829,000

'

'

'

38,631

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Schedule_of_Black_Scholes_Stoc

Schedule of Black Scholes Stock Option Pricing Model Weighted Average Assumptions (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	1.40%	0.80%	0.90%
Expected dividend yield	'	'	'
Expected life (in years)	'5 years 3 months 18 days	'4 years 8 months 12 days	'4 years 6 months
Volatility	102.00%	88.00%	97.00%

Stock_Option_Activity_for_All_

Stock Option Activity for All Stock Plans (Detail) (Stock Options, USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options	'	'	'
Options	'	'	'
Beginning Balance	307,000	156,000	34,000
Granted	4,352,000	179,000	126,000
Exercised	'	'	'
Forfeited	-112,000	-23,000	-2,000
Cancelled and expired	-28,000	-5,000	-2,000
Ending Balance	4,519,000	307,000	156,000
Vested or expected to vest	4,241,404	'	'
Weighted Average Exercise Price	'	'	'
Beginning Balance	$33.72	$90.07	$744.74
Granted	$1.71	$4.92	$5.48
Exercised	'	'	'
Forfeited	$2.40	$5.93	$9.91
Canceled and expired	$133.72	$886.13	$6,740.99
Ending Balance	$3.04	$33.72	$90.07
Exercisable	1,560,000	'	'
Vested or expected to vest	$3.12	'	'
Exercisable	$5.39	$89.08	$228.95
Weighted Average Remaining Contractual Term (Years)	'	'	'
Outstanding at end of period	'9 years 6 months 11 days	'	'
Vested and expected to vest at end of period	'9 years 6 months 11 days	'	'
Exercisable at end of period	'9 years 6 months 15 days	'	'
Aggregate Intrinsic Value	'	'	'
Outstanding at end of period	$889	'	'
Vested or expected to vest at end of period	842	'	'
Exercisable at end of period	$358	'	'

Summary_of_Status_of_Nonvested

Summary of Status of Nonvested Restricted Stock Awards (Detail) (Restricted stock, USD $)	12 Months Ended
	Dec. 31, 2013
Restricted stock	'
Nonvested shares	'
Beginning balance	3,322,000
Issued	6,375,000
Vested	-3,841,000
Forfeited	-1,168,000
Ending balance	4,688,000
Weighted Average Grant-Date Fair Value Per Share	'
Beginning Balance	$5.26
Issued	$1.21
Vested	$1.83
Forfeited	$3.70
Ending Balance	$2.95

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Benefit Plans [Line Items]	'	'	'
Maximum Percentage of the compensation eligible	80.00%	'	'
Discretionary matching contributions amount	$0.20	$0.20	$0.10

Shareholder_Rights_Plan_Additi

Shareholder Rights Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Shareholder Rights [Line Items]	'
Cash exercise price on Preferred Stock Rights	$8
Stockholder Rights Plan, Description	'Each right, if and when it becomes exercisable, will entitle the holder to purchase a unit consisting of one ten-thousandth of a share of Series ZZ Junior Participating Cumulative Preferred Stock, no par value per share, at a cash exercise price of $8.00 per unit, subject to standard adjustment in the Rights Plan. The rights will separate from the common stock and become exercisable if a person or group acquires 20% or more of our common stock. Upon acquisition of 20% or more of our common stock, the Board could decide that each right (except those held by a 20% shareholder, which become null and void) would become exercisable entitling the holder to receive upon exercise, in lieu of a number of units of preferred stock, that number of shares of our common stock having a market value of two times the exercise price of the right.
Percentage of rights held by single shareholder	20.00%
Redemption price of rights	0.0001
Right expiration date	3-Dec-15

Product_Sales_by_Major_Custome

Product Sales by Major Customers (Detail)	12 Months Ended
	Dec. 31, 2013
Customer A	'
Revenue, Major Customer [Line Items]	'
Product sales	67.00%
Customer B	'
Revenue, Major Customer [Line Items]	'
Product sales	4.00%
Customer C	'
Revenue, Major Customer [Line Items]	'
Product sales	3.00%

LongLived_Assets_Based_on_Geog

Long-Lived Assets Based on Geographical Locations (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property and equipment, net	$5,478	$6,785
UNITED STATES	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property and equipment, net	5,336	6,570
Europe	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property and equipment, net	$142	$215

Calculation_of_Basic_Diluted_N

Calculation of Basic & Diluted Net Loss Per Share Using Weighted Average Number of Shares Outstanding (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Computation Of Earnings Per Share Line Items	'	'	'	'	'	'	'	'	'	'	'
Net loss attributable to common shareholders	$10,196	($22,444)	($18,011)	($19,384)	($19,030)	($20,203)	($58,596)	($17,446)	($49,643)	($115,275)	($121,078)
Basic and diluted:	'	'	'	'	'	'	'	'	'	'	'
Weighted average shares outstanding	'	'	'	'	'	'	'	'	119,042	62,021	35,790
Less weighted average restricted shares outstanding	'	'	'	'	'	'	'	'	-4,847	-3,896	-1,496
Shares used in calculation of basic and diluted net loss per common share	'	'	'	'	'	'	'	'	114,195	58,125	34,294
Net loss per common share: Basic and diluted	'	'	'	'	'	'	'	'	($0.43)	($1.98)	($3.53)

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities excluded from computation of earnings per share amount	15.4	8.6	10.2

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (Aequus Biopharma, Inc, USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Affiliated Entity	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of ownership in subsidiary	61.00%	'	'
Amount funded in Aequus	$1.50	$0.60	$0.60
Convertible promissory Note Balance	$5.80	$4	'
Related Party, promissory note initial maturity date	'2012-05	'	'
Affiliated Entity | Until maturity	'	'	'
Related Party Transaction [Line Items]	'	'	'
Promissory note interest rate	6.00%	6.00%	6.00%
Affiliated Entity | In the event the note balance is not paid on or before the maturity date	'	'	'
Related Party Transaction [Line Items]	'	'	'
Promissory note interest rate	10.00%	'	'
James A. Bianco, M.D.	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of Ownership in Subsidiary	4.30%	'	'
Jack W. Singer, M.D.	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of Ownership in Subsidiary	4.30%	'	'
CTI, Telling	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of Ownership in Subsidiary	1.30%	'	'

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Jan. 31, 2014
VAT Assessments	'	'
Loss Contingencies [Line Items]	'	'
Range of possible loss, maximum	12,900,000	'
VAT Assessments | Subsequent Event	'	'
Loss Contingencies [Line Items]	'	'
Taxes payable	'	593,000
Payment date	'2014-03	'
CONSOB	'	'
Loss Contingencies [Line Items]	'	'
Range of possible loss, minimum	7,000	'
Range of possible loss, maximum	689,000	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Oct. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax [Line Items]	'	'	'	'
Increase Decrease in Valuation Allowance	'	$11,300,000	$113,500,000	$3,600,000
Net operating loss carryforwards maximum annual utilization amount	4,300,000	'	'	'
Gross Net Operating Losses	'	1,000,000,000	'	'
Available NOL carryforward after annual NOL limitation effect	'	$146,400,000	'	'

Reconciliation_Between_Effecti

Reconciliation Between Effective Tax Rate and Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Effective Tax Rate Reconciliation [Line Items]	'	'	'
Federal income tax rate	-34.00%	-34.00%	-34.00%
Research and development tax credits	-3.00%	'	-2.00%
I.R.C. Section 382 limited research and development tax credits	'	1.00%	'
Non-deductible debt/equity costs	'	'	1.00%
Non-deductible executive compensation	1.00%	1.00%	1.00%
I.R.C. Section 382 limited net operating losses	3.00%	134.00%	21.00%
Valuation allowance	27.00%	-111.00%	6.00%
Expired tax attribute carryforwards	'	7.00%	7.00%
Foreign tax rate differential	6.00%	1.00%	'
Other	'	1.00%	'
Net effective tax rate	'	'	'

Significant_Components_of_Defe

Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Net operating loss carryforwards	$49,777	$34,655
Capitalized research and development	31,046	36,303
Research and development tax credit carryforwards	1,486	223
Stock based compensation	12,097	10,813
Intangible assets	10,518	11,336
Depreciation and amortization	96	8
Other deferred tax assets	3,062	3,621
Total deferred tax assets	108,082	96,959
Less valuation allowance	-107,271	-95,949
Deferred Tax Assets, Net of Valuation Allowance, Total	811	1,010
Deferred tax liabilities:	'	'
GAAP adjustments on Novuspharma merger	-208	-208
Deductions for tax in excess of financial statements	-603	-802
Total deferred tax liabilities	-811	-1,010
Net deferred tax assets	'	'

Summary_of_Unaudited_Quarterly

Summary of Unaudited Quarterly Financial Data (Detail) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly financial data (unaudited)	'		'		'		'		'		'		'		'		'	'	'
Total revenues	$32,884	[1]	$362	[1]	$306	[1]	$1,126	[1]	'		'		'		'		$34,678	'	'
Product sales, net	520		362		306		1,126		'		'		'		'		2,314	'	'
Gross profit	487		349		270		1,071		'		'		'		'		'	'	'
Operating costs and expenses	-22,551		-15,942		-18,158		-19,553		-18,850	[2]	-15,149	[2]	-49,400	[2]	-18,098	[2]	-76,204	-101,497	-62,190
Net income (loss) attributable to CTI	10,196		-15,544		-18,011		-19,384		-18,601		-15,189		-50,138		-17,446		-42,743	-101,374	-62,360
Net income (loss) attributable to CTI common shareholders	$10,196		($22,444)		($18,011)		($19,384)		($19,030)		($20,203)		($58,596)		($17,446)		($49,643)	($115,275)	($121,078)
Net income (loss) per common share-basic	$0.08		($0.20)		($0.17)		($0.18)		($0.20)		($0.38)		($1.38)		($0.43)		'	'	'
Net income (loss) per common share-diluted	$0.08		($0.20)		($0.17)		($0.18)		($0.20)		($0.38)		($1.38)		($0.43)		'	'	'
[1]	Total revenues for the fourth quarter of 2013 include $27.4 million of license and contract revenue recognized in connection with the collaboration agreement with Baxter in November 2013 and $5.0 million of license and contract revenue from Teva in November 2013 upon the achievement of a worldwide net sales milestone of TRISENOX. See Note 14, Collaboration, Licensing and Milestone Agreements, for additional information.
[2]	Operating costs and expenses for the second quarter of 2012 include charges of $29.1 million of acquired in-process research and development related to our acquisition of assets from S*BIO. See Note 5, Acquisitions, for additional information.

Summary_of_Unaudited_Quarterly1

Summary of Unaudited Quarterly Financial Data (Parenthetical) (Detail) (USD $)	12 Months Ended		3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2013	Dec. 31, 2013
			Assets from S*BIO Pte Ltd.	Baxter	Teva
Quarterly Financial Data [Line Items]	'	'	'	'	'
License and contract revenue	$32,364	'	'	$27,364	$5,000
Acquired in-process research and development	'	$29,108	$29,108	'	'